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ABSTRACT
MOLECULAR BASES OF INHERITED BONE MARROW FAILURES:
SHWACHMAN-DIAMOND SYNDROME AND DIAMOND BLACKFAN ANEMIA
Adrianna Lee Henson
August 15, 2012
Inherited Bone Marrow Failure syndromes (IBMFS) are a heterogeneous
class of diseases that converge on very few subjects. They are unified by a block
in maturation of one or multiple blood lineages, are genetically inherited, and
have an increased incidence of cancers and myelodisplastic syndromes. Several
IBMFSs have been linked to defects in ribosome biogenesis. Diamond Blackfan
anemia (DBA) which presents with a macrocytic anemia has 10 known affected
genes all of which encode structural proteins of the large or small ribosomal
subunit. In contrast, there is only a single gene known to be involved in the
pathogenesis of Shwachman Diamond Syndrome (SDS) which usually presents
as exocrine pancreatic insufficiency along with neutropenia.
Investigation of DBA pathogenesis lead to the knowledge that deficiency
of certain ribosomal proteins leads to a specific defect in ribosomal pre-RNA
processing. In this work, we have identified a new DBA gene, RPL31, by isolating
mononuclear cells from the patient’s blood and subsequently harvesting total
RNA used for Northern blotting to identify delays in pre-rRNA processing in both
this patient as well as those found in a patient with other large subunit DBA
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mutations. Additionally, we have created a human cell model of SDS that has
allowed us to explore changes in respiration originally shown in yeast models. To
this end, we have identified increases in reactive oxygen species, changes in
oxygen consumption, mitochondrial membrane potential, and cell cycle delay, all
linked to depletion of SBDS protein.
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CHAPTER I
RIBOSOME DYSFUNCTION AND MARROW FAILURE

The Mammalian Ribosome: Structure and Function
The ribosome is responsible for translating the coded messages of mRNA
and catalyzing peptide bond formation between individual amino acids to
generate proteins. The ribosome thus functions as an enzyme, or ribozyme due
to its catalytic activity being embodied in its RNA rather than protein components
(Cech, 2000). Recent work on the crystal structure for the mammalian ribosome
has provided insight into the spatial arrangement of proteins and RNAs forming
this remarkable complex (Ben-Shem et al., 2010). The mammalian ribosome is
composed of four distinct ribosomal RNAs (rRNAs), and 80 ribosomal proteins
(RPs). Ribosomal proteins are named using the nomenclature of RPL for
proteins of the large ribosomal subunit and RPS for the small ribosomal subunit.
In addition to its structural components, ribosome synthesis requires more than
200 essential non-ribosomal trans-acting factors including both accessory
proteins and small nucleolar ribonucleoprotein particles (snoRNPs) (Jackson et
al., 2010). Large structures like ribosomes are often spoken of in terms of
Svedberg units based on their rate of migration in a centrifugal field, such as
40S, for the small ribosomal subunit. During protein synthesis, the 40S subunit
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binds to mRNA and scans down its length until it encounters an AUG start codon.
This complex, known as the 40S initiation complex, requires a number of
initiation factors and GTP to bind and once formed awaits the joining of a 60S
subunit to form the 80S initiation complex. Formation of the 80S initiation
complex requires energy, the recruitment of additional initiation factors, and the
release of others. Once formed, the 80S initiation complex is ready to enter the
elongation phase of protein synthesis as the ribosome translates down the
mRNA.
The production of ribosomal subunits is exquisitely regulated such that
equal amounts of 40S and 60S subunits are produced in response to a number
of physiologic, developmental, and environmental cues in amounts that are
proportional to the needs of the cell (reviewed in (Warner, 1990)). This process
is highly complex and occurs in a specialized organelle called the nucleolus,
which is found within the nucleus. Ribosome synthesis involves the coordinate
activities of RNA polymerase I and III producing RNA components of the
ribosome and RNA polymerase II producing transcripts for ribosomal proteins.
Ribosomal protein transcripts are translated in the cytoplasm and proteins
imported into the nucleus and subsequently travel to the nucleolus where the
rRNAs are being transcribed. Ribosome assembly occurs co-transcriptionally as
ribosomal proteins load onto nascent RNA polymerase I transcripts in forming
pre-ribosomal subunits. These pre-subunits continue to mature as additional
ribosomal proteins are incorporated, 5S rRNA produced by RNA polymerase III is
also incorporated into maturing 60S subunits. Ribosome biogenesis also
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requires post transcriptional and post translational modifications of ribosomal
RNA and protein, respectively. Finally, additional factors are involved in subunit
transport from the nucleus to the cytoplasm (Zemp and Kutay, 2007).

Pre-rRNA processing
Three of the four mature rRNAs are synthesized from a large polycistronic
45S pre-rRNA transcript synthesized by RNA polymerase I. This organization
assures the equimolar production 18S, 5.8S and 28S RNA components of the
ribosome. Only the 5S rRNA, transcribed by RNA polymerase III, is not found in
this organizational unit. In yeast, the rDNA unit includes coding regions for both
5S rRNA and the 45S RNA. This coding unit is repeated from 30 to 500 times in
the genome and this spatial organization may allow the coordination of RNA
polymerase I and III activities in producing the four rRNAs. In mammalian cells,
the 5S rDNA is not physically linked to the remaining rDNA repeat units. The
rDNA repeats are clustered at various sub-telomeric regions on different
chromosomes. The basis for locating 5S rDNA independently of the other rDNA
repeat units in many higher organisms, including humans, is unknown (Ciganda
and Williams, 2011).
In addition to the mature 18S rRNA of the 40S subunit and the 5.8S and
28S rRNAs of the 60S subunit, the 45S pre-rRNA contains external flanking
sequences (ETS: external transcribed sequences) and two internal transcribed
sequences (ITS1 and ITS2). Thus, to liberate the mature rRNA species the 45S
pre-rRNA must undergo a series of endo- and exonucleolytic processing steps
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which occur concurrently with the assembly of ribosomal proteins onto nascent
transcripts. Other processing events occur co-transcriptionally to the 45S prerRNA including methylation and pseudouridinylation (Fromont-Racine et al.,
2003). The current view of the numerous steps involved in the maturation of
mammalian 45S pre-RNA are outlined in a simplified version in Fig. 1. The vast
majority of these processing steps occur in the nucleolus although some later
steps in maturation occur in the cytoplasm (Flygare et al., 2007). Limiting the
amount of many of the factors required for ribosome synthesis have been shown
to cause delays in maturation of pre-rRNA as evidenced by the accumulation of
distinct pre-rRNA intermediates. For example, when one copy of RPS19 is
mutated in patients with an inherited bone marrow failure syndrome (IBMFS),
Diamond Blackfan anemia (DBA), there is a delay in the maturation of the 3′ end
of 18S rRNA which can be visualized by Northern blotting as an increase in 21S
pre-rRNA (Flygare et al., 2007). This strategy of employing Northern blot
analysis to identify specific defects during the process of ribosome synthesis is
used throughout the first part of this dissertation. This will be discussed in more
detail in subsequent chapters and Northern blot oligonucleotides used in this
dissertation to identify processing defects in pre-rRNA resulting from mutations
in genes encoding ribosomal proteins are shown in Table 1 of Chapter 2.
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Fig 1: Mature rRNAs are liberated from a large polycistronic transcript by a
series of endo and exonucleolytic cleavage steps.
The 45S pre-rRNA transcribed by RNA polymerase I is shown at the top of the
figure. This transcript undergoes multiple exonuclease and endonuclease
processing steps to form mature 18S, 5.8S, and 28S rRNAs. The pathway
shown here is the major pathway found in mononuclear cells derived from human
blood and in the TF-1 human erythroleukemia cell line.
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Synthesis of Ribosomal Subunits
While pre-rRNA processing is a way of tracking different steps in ribosome
synthesis, these processing events are only a small part of the overall process of
ribosome synthesis that begins with nucleolar transcription by RNA polymerase I
and ends with functional ribosomal subunits in the cytoplasm. The “Christmas
tree” appearance of pre-rRNA transcription was described decades ago (Miller
and Beatty, 1969). These nascent transcripts begin at rDNA promoters and get
longer the further they extend from the initiation site. The high transcription rates
of rDNA in rapidly dividing cells give rise to numerous pre-rRNAs being
transcribed simultaneously giving the characteristic Christmas tree appearance.
More detailed Miller spreads of rDNA transcription units in eukaryotic cells have
revealed that these nascent pre-rRNA transcripts begin to ball up as ribosomal
proteins and various trans-acting factors assemble co-transcriptionally on the
45S pre-rRNA (Miller and Beatty, 1969).
The earliest complex in the process of ribosome synthesis that can be
biochemically identified is the 90S pre-ribosomal particle. This complex includes
the small subunit processome (SSU) which gathers on the 18S rRNA domain at
the 5′-end of the 45S pre-rRNA. The SSU includes the U3 snoRNP which is
involved in promoting endonucleolytic cleavages in the 5′-ETS and ITS1 and so
plays a critical role in the maturation of the 40S ribosomal subunit (Dragon et al.,
2002).

Although numerous ribosomal proteins and factors required for the

assembly of the 40S subunit are found in the 90S species, no large subunit
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ribosomal proteins or 60S trans-acting factors are found in this early complex
(Gavin et al., 2002; Grandi et al., 2002).
After the 90S species goes through the processing steps in ITS1, the
pre-40S subunits separate from the pre-60S subunit to begin further independent
steps in subunit maturation. Pre-40S subunits containing an immature 20S prerRNA recruit additional proteins as maturation continues, and pre-40S subunits
are transported out of the nucleus. For example Tsr1 is necessary for processing
of 20S pre-rRNA and the export of pre-40S subunits from the nucleus, even
though it is present in the 90S complex. Tsr1 must be added to the pre-40S
complex after its release from the 90S complex. Many trans-acting factors
associated with the pre-40S subunits are released before exiting the nucleus
(Jackson et al., 2010; Moy and Silver, 2002; Panse, 2011).
The formation of 60S subunits is considerably more complicated than that
of the 40S subunit and involves the maturation of three rRNA species, the
incorporation of over 30 ribosomal proteins, and requires over 100 trans-acting
factors. Maturation of 60S subunits begins in the nucleolus but is eventually
completed within the cytoplasm. After the pre-40S and pre-60S subunits are
formed, the two subunits undergo divergent processing steps on their way to the
nuclear pore complex where NESs (nuclear export sequences) present on both
pre-subunits are recognized by the export factor Xpo1, also known as Crm1 (Hurt
et al., 1999; Moy and Silver, 1999, 2002; Stage-Zimmermann et al., 2000). The
molecules of the pre-40S subunit that are recognized by Crm1 include Ltv1,
Dim2, and Rio2, the only trans-acting factor with a NES known to be associated
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with pre-60S subunits is Nmd3 (Ribbeck and Gorlich, 2002; Seiser et al., 2006;
Zemp et al., 2009).
There are several factors that are not associated with the mature 60S
subunit that are part of the late cytoplasmic maturation of pre-60S subunits such
as two GTPases: Lsg1/Kre35 and Eif1, two ATPases: Drg1 and Jjj1-Ssa1/Ssa2, a
Zn2+ finger protein: Rei1, and a phosphatase: Yvh1 (Panse and Johnson, 2010).
Most of these factors prevent the premature joining of 40S and 60S subunits until
maturation is completed within the cytoplasm. Of particular interest to this
dissertation is the GTPase Efl1. Shwachman-Bodian Diamond syndrome
protein, SBDS, along with Efl1 are required for release of the anti-association
factor eIF6 from pre-60S subunits in the cytoplasm (Menne et al., 2007;
Valenzuela et al., 1982; Zemp et al., 2009). The pre-60S subunits that emerge
from the nucleus contain the anti-association factor eIF6 and the hydrolysis of
GTP by Efl1 in association with SBDS is required for eIF6 release so 60S
subunits can participate in translation. This release is also necessary for eIF6 to
be recycled back to the nucleus to function in transporting more pre-60S subunits
to the cytoplasm (Basu et al., 2001; Finch et al., 2011; Gandin et al., 2008;
Miluzio et al., 2009; Senger et al., 2001; Wong et al., 2011).

Overview of translation
Ribosomes and associated factors carry out the process of translation, the
means by which nucleotide triplets within a mRNA dictate the synthesis of
proteins via the genetic code. Initiation is the process by which appropriate AUG
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codons are identified in mRNAs and 80S ribosomes with initiator-tRNA bound to
the P site are poised to begin the process of translational elongation. The most
tightly regulated steps of translation are typically found during the initiation phase
(Jackson et al., 2010; Sonenberg and Hinnebusch, 2009). There is both a
canonical and non-canonical pathway of eukaryotic initiation. The canonical
pathway begins with the formation of the ternary complex including eIF2, GTP,
and an initiator transfer RNA charged with a Met-tRNAMeti . This complex joins
with a 40S subunit already bound to eIF1, which together with eIF1A, eIF3, and
eIF5 form the 43S pre-initiation complex. The mRNA is recognized through 5’cap structures by the eIF4F complex (eIF4F bound to eIF4E, eIF4G, eIF4A).
This complex recruits the helicase eIF4B which can melt RNA secondary
structures in an ATP-dependent fashion. The 43S pre-initiation complex is then
able to bind the mRNA/eIF4F complex and begins the process of scanning from
the 5’ end of the mRNA towards the 3’ end until the complex finds a suitable
AUG.
When the scanning complex localizes the AUG start codon in what will
become the P (peptidyl) site, eIF1 is released, and eIF5 facilitates the hydrolysis
of eIF2-GTP to eIF2-GDP. After eIF2-GDP is released, the 60S subunit is able to
join with the 48S complex and eIF5B subsequently mediates the release of eIF1,
eIF3, eIF4B, eIF4F, and eIF5. Next, eIF5B-GTP is hydrolyzed to eIF5B-GDP and
eIF5B-GDP and eIF1A are released. The 80S initiation complex is now ready to
move to the elongation phase of translation. After translation is complete,
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termination occurs and many of the components of the translational machinery
are recycled to participate in translation of other mRNAs (Jackson et al., 2010).
The alternative pathway of initiation involves mRNA elements called
internal ribosome entry sites (IRES). Initially identified in viral mRNAs, these
structures are able to recruit translational machinery without the normal initiation
complex formation. By employing these alternative strategies for translational
initiation viruses are able to co-opt a host’s translational machinery to their own
ends. As is typically the case, it was eventually shown that host cells also
employ these alternative strategies for translational initiation, but do so
infrequently as forms of regulation at specific points in development, cell cycle
progression, or in response to stress (Jackson et al., 2010).

Peptide Bond Formation: Elongation
Once the 80S initiation complex is formed, and the Met- tRNAMet i is in the
P site, elongation can commence. The next codon downstream of the initiator
AUG is used to specify which aminoacyl-tRNA will productively enter the A
(aminoacyl) site of the complex in a ternary complex with EF1A and GTP. Once
GTP is hydrolyzed and EF1A is released, a peptide bond is formed between the
amino acids, then the ribosome shifts one codon toward the 3’ end catalyzed by
EF2 and GTP hydrolysis, the A site is open and the newly synthesized peptidyltRNA is translocated to the P site. The deacylated tRNA formerly occupying the
P site exits the ribosomal complex through the E (exit) site (Cech, 2000).
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Elongation continues in most cases until the ribosome encounters a stop codon
in the A site and termination occurs.
Numerous human diseases have been linked to defects in the production
of ribosomes or in the process of translation. The focus of this dissertation will be
on diseases linked to defects in ribosome synthesis. The inherited bone marrow
failure syndromes as a class appear to be driven to varying extents by defects in
the synthesis in ribosomes. Some notable exceptions to this general statement
are discussed in the following section.

Bone Marrow Failure syndromes and Other Ribosomopathies
Inherited Bone Marrow Failure syndromes (IBMFSs) are a heterogeneous
array of diseases that have in common a failure to produce one or multiple blood
lineages and are often associated with a significant cancer predisposition well
above that of the general population. The IBMFS also have certain unique
features of presentation and pathophysiology characteristic of their specific
disease. The IBMFSs discussed in detail below include Fanconi Anemia (FA),
Diamond Blackfan anemia (DBA), Dyskeratosis Congenita (DC), Shwachman
Diamond syndrome (SDS), Severe Congenital Neutropenia (SCN), and Pearson
Syndrome. Many of these syndromes have molecular defects in ribosome
synthesis that contribute to disease pathophysiology and are given the
designation of “ribosomopathies.” DBA and SDS will be the primary focus of this
dissertation.
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Hematopoiesis
Hematopoiesis refers to the generation of mature blood cells from the
long-term hematopoietic stem cell (LT-HSC) progenitor. In adults this takes place
in the bone marrow where HSCs divide to form more HSCs, the self-renewing
property common to all stem cells, as well as differentiate to form committed
progenitors (Metcalf, 2007). Mature cells of the hematopoietic system include
lymphocytes, granulocytes, monocytes, megakaryocytes, and erythrocytes.
Lymphocytes include both T and B cells central to immune system function. T
cells are antigen recognition and antigen presenting cells whose final maturation
takes place in the thymus, while B cells fully differentiate in the bone marrow and
produce antibodies important in phagocytosis and the complement system of
immunity. Granulocytes, also called polymorphonuclear cells (PMN), include
eosinophils released to sites of allergy or parasitic infection. Neutrophils are
phagocytic and engulf pathogens such as opsonized bacteria and use their
specialized set of enzymes such as NADPH oxidases and myeloperoxidases
(MPO) to generate ROS in phagolysosomes and destroy the bacteria. Basophils
respond to inflammation and release heparin, an anticoagulant.

Monocytes

differentiate into macrophages and dendritic cells in the spleen and function by
phagocytosing pathogens. The most common while blood cells in circulation are
neutrophils. Megakaryocytes release platelets important in forming blot clots.
Erythrocytes are the transporters of hemoglobin, the primary oxygen carrier in
the body (Metcalf, 2007).
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The first maturation step from the hematopoietic stem cell splits the
lineages for lymphocytes (common lymphoid progenitor, or CLP) and all other
blood cell types (common myeloid progenitor, or CMP). The CLP will then
differentiate into a lineage specific pre-B cell or pre-T cell. The differentiation of
the myeloid lineage is much more complex. The CMP first becomes either a
MEP (megakaryocyte erythroid progenitor) or a GMP (granulocyte macrophage
progenitor). The MEP further differentiates into Meg-CFC and then
megakaryocytes, which generate platelets, or BFU-E (burst forming units erythroid). The BFU-E give rise to CFU-E (colony forming units erythroid) and
eventually mature erythrocytes. The GMP further differentiates into either the
Mast-CFC that will become a basophil, the eosinophil CFC (Eo-CFC), or the
granulocyte macrophage CFC (GM-CFC). The GM-CFC differentiates into two
lineages, the granulocyte CFC (G-CFC) that will become neutrophils or the
macrophage CFC (M-CFC) that will become monocytes (Metcalf, 2007). The
process of differentiation is dependent not only on cytokines or growth factors
that drive the formation of the various blood lineages, but also the complex
stromal environment of the bone marrow niches through an interplay of multiple
types of regulation of numerous cell types in the marrow (Bianco, 2011). Recent
evidence obtained from mouse studies indicated that there are several classes of
LT-HSCs with predispositions for differentiation toward specific blood lineages,
adding additional levels of complexity (Cavazzana-Calvo et al., 2011). Inherited
bone marrow failure syndromes all have a pathological defect in one or multiple
steps during the maturation process outlined above.
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Diamond Blackfan Anemia: Pathophysiology
Diamond Blackfan anemia (DBA) is a macrocytic normochromic anemia
that most commonly manifests in infancy. In addition to red blood cell
hypoplasia, up to 40% of patients also have a congenital defect, with 25% having
multiple anomalies. The most common anomalies are short stature, craniofacial
defects, triphalangeal or bifid thumbs, and deformities of the urogenital and
cardiovascular systems (Vlachos et al., 2008). The first link between DBA and
the ribosome came in 1999 when a chromosomal translocation in a DBA patient
was shown to inactivate RPS19, (Ribosomal Protein of the Small subunit number
19) a gene encoding a structural component of the 40S ribosomal subunit
(Draptchinskaia et al., 1999). RPS19 remains the most common target of
inactivating mutations in DBA, compromising approximately 25% of the patient
population. To date, pathogenic mutations have been identified in nine additional
genes encoding ribosomal proteins of both the large (60S: RPL5, RPL11,
RPL35a, RPL26) and small (40S: RPS7, RPS10, RPS17, RPS24, RPS26,)
subunit (Farrar et al., 2011; Gazda et al., 2012; Vlachos et al., 2008). In each
case, mutations identified are found in the heterozygous state indicating that
DBA is the result of haploinsufficiency for the affected ribosomal protein. The
view of DBA as a ribosomopathy became inexorable when the gene responsible
for the refractory anemia in patients with the myelodysplastic 5q - syndrome was
shown to encode ribosomal protein S14 (RPS14) (Ebert et al., 2008). Only
limited genotype/phenotype relationships have been identified so far in DBA
patients. The most notable is that patients with RPL5 and RPL11 mutations in
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general display a much more severe phenotype including a high prevalence of
cleft lip and cleft palate.
Though it has been over a decade since DBA pathogenesis was originally
linked to deficiencies of ribosomal proteins, the mechanisms underlying disease
pathophysiology, in particular the tissue specificity of disease presentation
remain unclear. It has been well established that reduced quantities of a
ribosomal protein can interfere with the assembly of the subunit to which it is a
part. For example, cell culture models have shown that reducing the level of
expression of RPS19 interferes with the biogenesis of 40S subunits and gives a
well-defined signature of RPS19 dysfunction in pre-rRNA processing. This prerRNA processing signature associated with RPS19 deficiency is also evident in
cells from the bone marrow of DBA patients (Flygare et al., 2007). Pre-rRNA
processing signatures have been associated with other ribosomal proteins
affected in DBA. The specific signature for a given ribosomal protein will depend
on which rRNA (or pre-rRNA) it becomes initially associated with, and also, in the
case of the larger rRNAs, which sub-assembly domain of the rRNA contains the
protein. Together, these data indicate that ribosome assembly is defective in
individuals haploinsufficient for ribosomal proteins, and defective ribosome
assembly lies at the heart of DBA pathophysiology.

Molecular Mediators of DBA
During normal ribosome biogenesis, ribosomal proteins and rRNA are
joined in a specific temporal and spatial sequence to form mature ribosomal
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subunits (Warner and McIntosh, 2009). In order to coordinate the generation of
ribosomes with the needs of the cell, there are multiple connections between
ribosome synthesis and cell division, nutrient availability, and apoptosis (Dai and
Lu, 2008; Dai et al., 2004; Fernandez et al., 2002; Lindstrom et al., 2007; Sun et
al., 2007). Ribosomal proteins that are synthesized in excess of that needed for
subunit assembly are frequently rapidly degraded (Lam et al., 2007). It has now
become clear that certain ribosomal proteins have novel, extra-ribosomal,
functions when they are not incorporated into ribosomal subunits (Warner and
McIntosh, 2009). Several of these ribosomal proteins influence the delicate
balance between cell survival and apoptosis through their interactions with the
oncogene MDM2 (murine double minute two oncogene, whose human ortholog
is HDM2). MDM2 is an E3 ubiquitin ligase that can target p53 for proteosomal
degradation and is one of the exquisitely sensitive primary regulators of p53
stability (Clegg et al., 2008). RPL11, RPL5, RPL23, RPL26, RPS3, and RPS7
are all capable of binding MDM2 during “ribosomal stress.” Ribosome stress can
be induced by a variety of effectors including treatement with actinomycin D, an
RNA polymerase I inhibitor. Under these conditions ribosomal proteins are free
to interact with and inhibit MDM2 resulting in p53 stabilization and activation
(Chen et al., 2007; Dai and Lu, 2004; Dai et al.; Dai et al., 2004; Fumagalli et al.,
2009; Horn and Vousden, 2008; Ofir-Rosenfeld et al., 2008; Sun et al., 2007;
Yadavilli et al., 2009; Zhang et al., 2003; Zhu et al., 2009).
In addition to ribosomal proteins, there is growing evidence to suggest that
5S rRNA plays a role in ribosome stress signaling. The 5S rRNA is distinct in that
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it is transcribed by RNA polymerase III independent of the rDNA repeat as
transcribed by the polycistronic RNA polymerase I transcript containing the other
three rRNAs. 5S rRNA forms a complex with RPL5, and possibly RPL11, prior to
the incorporation of this subcomplex into the assembling 60S subunit (Zhang et
al., 2007). Intriguingly, the subcomplex of RPL5, RPL11, and 5S rRNA binds
more effectively to MDM2 than each of the individual components alone. The
synergistic interaction of this subcomplex with MDM2 could potentially play a
major role in signaling abortive assembly of the 60S ribosomal subunit leading to
p53 stabilization and activation as shown in Fig 2. This observation is potentially
of fundamental importance to mechanisms underlying DBA pathophysiology,
because erythrocyte precursors in the bone marrow of patients show a proapoptotic phenotype which appears linked to p53 activation (Lipton et al., 1986;
Nathan et al., 1978; Ohene-Abuakwa et al., 2005; Perdahl et al., 1994). Thus,
this pathway is hypothesized to be the cornerstone linking defective ribosome
assembly to the pro-apoptotic phenotype of erythroid progenitors in the marrow
of patients with DBA.
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Fig. 2: The 5S rRNA subcomplex as a critical mediator of ribosome stress
signaling to p53 activation.
When ribosomal proteins become limiting, such as in the setting of ribosomal
haploinsufficiency in DBA pathogenesis, ribosomal proteins are free and are
capable of interacting with MDM2 leading to p53 activation. In the setting of
haploinsufficiency for a large subunit ribosomal protein the 5S rRNA subcomplex
may play a critical role in ribosomal stress signaling. It is less clear which factors
play vital roles in ribosomal stress signaling when small subunit ribosomal protein
genes are affected in DBA or when mutations are found in either the RPL5 or
RPL11 genes (Lipton and Ellis, 2009).
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Previous Animal Models of DBA

Generation of an animal model that recapitulates both the hematological
and ribosomal defects associated with DBA patients has proven challenging. A
knockout mouse would seem the obvious choice in a disease marked by
haploinsufficiency for ribosomal protein genes. The heterozygous Rps19 mouse
model, showed no detectable phenotypes, and the homozygous mutant led to
early embryonic lethality (Matsson et al., 2004). The first animal models of DBA
that showed a blood lineage defect were created in zebrafish (Danilova et al.,
2008; Uechi et al., 2008). Zebrafish have several advantages as an animal
model for hematology. The transparent embryos make iron-containing
substances, such as the heme in the hemoglobin of mature red blood cells,
easily visualized. The externally fertilized embryos provide an easy conduit for
over or under expressing a gene of interest. Zebrafish models have allowed for
high throughput drug screening and localization of genetic modifiers. Though
many advances have been made possible through study of zebrafish models,
there are also several important differences in zebrafish blood development
when compared to human processes. The sites of blood lineage development in
zebrafish are far removed from their localization in humans. Hematopoietic stem
cells (HSCs) in zebrafish are found in kidney marrow rather than the bone
marrow as in mammals (Carradice and Lieschke, 2008; Jing and Zon, 2011).
The first mammalian model of DBA with an erythroid defect was
serendipitously discovered during a screen for mutations that cause dark-skinned
footpads in mice (McGowan et al., 2008). Two causative mutations in the screen
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were identified as ribosomal protein genes, Dsk3 as Rps19, and Dsk4 as Rps20.
Only Rps19 is a known DBA gene. After this discovery, the authors identified a
very mild anemia in the affected mice. Subsequently, they reversed pathological
findings in an Rps6 heterozygous knockout mouse by inhibition of p53 function, a
common theme recognized among putative animal models of DBA (Ball, 2011;
Boultwood et al., 2011; Danilova et al., 2008; Jaako et al., 2011; McGowan et al.,
2011). The validity of an Rps6 heterozygous mouse to study DBA is diluted by
the lack of an identified mutation in RPS6 in a DBA patient, as well as the
specialized function of Rps6 as a downstream target fr phosphorylation by the
mTOR pathway (Magnuson et al., 2012).
A more recent mouse model expressed a Rps19R62W point mutation
found in a DBA family pedigree. It has been hypothesized that this mutation may
function in a dominant negative manner (Devlin et al.). This particular model
linked inducible expression of this modified allele in a normal mouse genetic
background to some of the blood lineage defects seen in DBA patients but also
differed in certain important respects. These mice lack some of the key prerRNA processing defects seen in DBA patients with known RPS19 mutations, as
well as a block in blood progenitor maturation at a different stage of development
than those seen in bone marrow specimens from DBA patients (Flygare et al.,
2007). Thus, none of the currently available animal models of DBA are entirely
adequate and improvements are still needed. Our contribution to this gap are
represented in chapter two of the appendix, which details our role in the

20

validation of ribosome defects in a novel mouse model of DBA (Jaako et al.,
2011).

Shwachan Diamond syndrome (SDS)
Shwachman Diamond syndrome typically presents in early infancy, but
has also been diagnosed in adolescents. The most common presenting
symptom is malabsorption of fat from the diet due to pancreatic insufficiency and
the associated decrease in amylase, trypsinogen, and lipase production. The first
case of SDS was described as pancreatic insufficiency with bone marrow
dysfunction and the two symptoms remain the diagnostic criteria in the present
day (Rothbaum et al., 2002; Shimamura and Alter, 2010; Shwachman et al.,
1964). Most patients have a neutropenia that upon analysis of bone marrow
samples reveals a hypocellular bone marrow with decreased myeloid
progenitors, but the initial neutropenia often presents later than the symptoms of
malabsorption. The neutropenia severity shows a wide range of variation among
patients (Shimamura and Alter, 2010). In addition to neutropenia, multiple other
blood lineages can be affected in SDS, with more severe disease courses
leading to aplastic anemia, eventual myelodisplastic syndrome (MDS), or acute
myelogenous leukemia (AML) (Berthou et al., 1991; Shimamura and Alter, 2010).
The most frequent causes of death in SDS patients are sepsis, due to the
neutropenia, or AML. Unfortunately the median age of survival is currently 36
years old (Shimamura and Alter, 2010).
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SDS Genetics
Biallelic mutations in SBDS (Shwachman Bodian Diamond Syndrome)
have been identified in over 90% of SDS patients (Boocock et al., 2003). The
disease is inherited in an autosomal recessive pattern. There are no cases
associated with homozygous null mutations and homozygous loss of Sbds in
mouse models is embryonically lethal (Zhang et al., 2006). Most mutations are
thought to be hypomorphic alleles that arose from conversion with an adjacent
pseudogene SBDSP (Shammas et al., 2005). The most common mutations are
in exon 2, and include c.183_184insCT or c. 258+2T>C on separate genes, or
the combination of the two mutations in the same gene. Seventy-six percent of
patients have at least one of these three mutations and 62% have both (Boocock
et al., 2003).

SBDS Protein Functions
The SBDS protein is evolutionarily conserved across eukaryotes and
many archaebacteria (Boocock et al., 2003; Menne et al., 2007; Ng et al., 2009;
Shammas et al., 2005). First clues as to the function of SBDS came from the
finding that certain archaebacterial orthologs were found in operons containing
genes involved in RNA metabolism. Included among these genes were ones
encoding proteins involved in pre-rRNA processing. Studies on the yeast
ortholog of SBDS, Sdo1, revealed a role for Sdo1 in the maturation of 60S
ribosomal subunits (Menne et al., 2007). Specifically, Sdo1 plays a role in
releasing the anti-association factor Tif6 from nascent pre-60S subunits entering
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the cytoplasm. The failure to release Tif6, also limits its recycling back to the
nucleus where it is involved in the nucleocytoplasmic transport of pre-60S
subunits. These combined effects severely limit the production of functional 60S
subunits in cells depleted of Sdo1. Recent studies in mammalian cells have
shown related functions for SBDS in the maturation of 60S ribosomal subunits
(Wong et al., 2011).
In addition to its role in the maturation of 60S ribosomal subunits, SBDS
has been implicated in a number of additional cellular processes The SBDS
protein has been shown to colocalize with the mitotic spindle, and cell models
expressing mutant versions of the protein analogous to SDS patient mutations
have been shown to have altered SBDS cellular localization. This is proposed as
an instigator of genomic instability in SDS, a putative pathway leading to AML
(Austin et al., 2008; Maserati et al., 2009; Orelio et al., 2009). Changes in
cellular localization are hypothesized to occur via modifications in the
SUMOlyation domain at the C-terminus of the protein (Orelio et al., 2011). Bone
marrow progenitor cells show an increased propensity for apoptosis, and cellular
models of SDS have shown an increased sensitivity to Fas (a ligand for death
domain receptors that activate downstream caspase cleavage and result in
apoptosis) and changes in cellular localization of Fas when stimulated
(Rujkijyanont et al., 2009; Rujkijyanont et al., 2008; Watanabe et al., 2009).
Other changes in cell function with mutations in SBDS include the
decreased ability of neutrophils to polymerize F-actin in response to appropriate
cellular stimuli (Orelio and Kuijpers, 2009), increased reactive oxygen species
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(ROS) production (Ambekar et al., 2010), and changes in the bone marrow
stromal environment (Raaijmakers et al., 2010). Bone marrow from SDS patients
show an intrinsic defect in the maturation of blood progenitors (Dror and
Freedman, 1999). The dyscrasias found in patient bone marrow samples are
due to defects not only in the hematopoietic cells, but also in the stromal cells
that support the differentiation of stem cells as evidenced by bone marrow
transplant studies in animal models (Rawls et al., 2007). Clearly, any of these
multiple functions of the SBDS protein could contribute to the clinical features of
SDS.

Dyskeratosis Congenita (DKC)
Dyskeratosis Congenita occurs in X-linked as well as autosomal dominant
and autosomal recessive inheritance patterns. Clinical findings include
dystrophic nails, oral leukoplakia, lacy reticular pigmentation, lacrimal duct
stenosis, sparse and/or gray hair, poor dentition, development delay, esophageal
stenosis, and avascular necrosis of the hip (Alter, 2007; Berthou et al., 1991; Liu
and Ellis, 2006; Narla and Ebert, 2010; Savage and Alter, 2009; Savage et al.,
2009; Tamary et al., 2010). Criteria for diagnosis include measurement of
telomere length, as DKC patients usually have telomeres that fall within the very
lowest percentile of telomere length for age matched controls. With age their risk
for aplastic anemia and MDS increases much more dramatically than the rest of
the population (Alter et al., 2010; Alter et al., 2009; Du et al., 2009; Gadalla et al.,
2010; Heiss et al., 1998; Savage and Alter, 2008, 2009; Savage et al., 2009;
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Tamary and Alter, 2007; Tamary et al., 2010). Bone marrow inspection usually
reveals hypocellular bone marrow with decreased megakaryocytes. Bone
marrow failure is the leading cause of death in DKC (Narla and Ebert, 2010).
Pathogenic mutations in DKC patients have been identified in six genes that all
function in the maintenance of telomeres. Many of the genes mutated in DKC
produce products that perform multiple functions in the cell. Mutations in DKC1
have an X-linked recessive inheritance pattern, and this particular mutation leads
to defects in ribosome biogenesis due to the functions of dyskerin as a member
of the snoRNP complex that is required for psuedouridylation of pre-rRNA. In
addition to its function in maturation of rRNA, dyskerin is also associated with
other proteins, such as TERT, and RNAs, such as TERC, to form the telomerase
complex that protect the telomeres found at the end of chromosomes (Heiss et
al., 1998; Knight et al., 1998). Mutations in TERT can be inherited in autosomal
dominant and autosomal recessive inheritance patterns, while TINF2 and TERC
have only been shown in autosomal dominant patterns, and N0P10/NOLA3 and
NHP2/NOLA2 are autosomal recessive. Except for the mutations in dyskerin
none of the other mutations in DKC genes are thought to affect ribosome
function. Interestingly, the X-linked form of the disease is typically more severe
than the other forms indicating that effects on ribosome synthesis can modify the
clinical phenotype in this, and perhaps other disorders.
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Cartilage Hair Hypoplasia (CHH)
Cartilage Hair Hypoplasia (CHH) was first described as a dwarfism in an
isolated Amish population (McKusick et al., 1965). In such isolated Amish
populations and certain Finnish populations there is an increased incidence of
CHH, but it is very rare in the general population (Makitie, 1992; Ridanpaa et al.,
2002). It most commonly presents with skeletal dysplasias, immune dysfunction,
hypoplastic hair, and increased cancer susceptibility. One or multiple blood
lineages can be affected, with cells of the myeloid lineage being most commonly
affected (Ganapathi and Shimamura, 2008). Autosomal recessive inheritance
patterns are seen with mutations in RMRP encoding the RNA component of
RNAse MRP (mitochondrial RNA processing complex). This RNase has a
number of targets including the cyclin B2 mRNA, mitochondrial RNA, and a
cleavage within ITS1 of 45S pre-rRNA giving rise to the mature 5′ end of 5.8S
rRNA. Mutations in RMRP that predominantly affect pre-rRNA processing most
commonly cosegregate with skeletal dysplasias, whereas mutations that
selectively affect cyclin B2 mRNA cleavage give rise to the immune deficiencies
(Theil et al., 2011). Management is primarily supportive care, but transplant may
be indicated in very severe cases (Narla and Ebert, 2010).

Treacher Collins syndrome (TCS)
Treacher Collins syndrome (TCS) is usually recognized shortly after birth
due to its characteristic set of facial features and was initially described by an
ophthalmologist over a century ago (Collins, 1900). Deformations are caused by
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inadequate migration of neural crest cells during fetal development (Dixon et al.,
2006) leading to downward lateral slanting palpebral fissures (outer corners of
the eyelid), abnormal ear development with hearing loss as a common side
effect, hypoplasia of the maxillary and malar portions of the skull leading to a
flattening of the mid-face and micrognathia (abnormally small jaw) and cleft
palate (Narla and Ebert, 2010). The management of these patients requires the
attentive care of numerous types of physicians due to the complications that are
associated with such physical anomalies (Posnick and Ruiz, 2000). Many of the
craniofacial defects seen in TCS are reminiscent of those seen with RPL5 and
RPL11 mutations in DBA (Narla and Ebert, 2010).
Mutations in the gene TCOF1 that encodes the protein treacle were linked
to this autosomal dominantly inherited condition (Jill Dixon, 1996). Treacle binds
to rDNA and upstream binding factors required for the transcription of the 45S
polycistronic pre-rRNA sequence (Valdez et al., 2004). It also appears necessary
for methylation of the 45S pre-rRNA. More recently, mutations in genes encoding
critical shared polypeptides between RNA polymerase I and III have been
identified in TCS patients (Valdez et al., 2004). This observation indicates that
defects in RNA polymerase I transcription likely underly disease pathophysiology.
A mouse model haploinsufficient for Tcof1 demonstrated that the defects in
neural crest cell migration and neural epithelial apoptosis are instrumental in
creating the physical findings pathognomonic of TCS (Dixon et al., 2006). The
craniofacial defects can be rescued by inhibiting p53 function during fetal
development, even if the ribosomal defects are not corrected (Jones et al., 2008).
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One of the more surprising aspects of the relationship between TCS and
DBA is the fact that TCS patients do not exhibit bone marrow failure. The
pathophysiologic mechanism underlying current views of DBA involve free
ribosomal proteins interacting with MDM2 to activate p53. Much of the
experimental support for this mechanism comes from in vitro cell culture work
using Actinomycin D, an inhibitor of RNA polymerase I (Aktipis and Panayotatos,
1981; Casse et al., 1999). Nevertheless, these studies seem more relevant to
the pathophysiologic mechanisms underlying TCS. How then can we reconcile
the fact that investigators in both fields appear to be employing the same
pathophysiologic mechanisms for distinct diseases? While there is some overlap
in clinical presentation between the two disorders, specific craniofacial anomalies
observed in DBA are restricted to specific ribosomal protein genotypes, whereas,
potentially even more critically TCS lacks an associated bone marrow failure
(Shimamura and Alter, 2010). Clearly, investigators are missing something when
ribosomal protein defects give rise to one disease and ribosomal RNA defects
give rise to another and both disease phenotypes can be rescued by inactivating
p53.

Fanconi Anemia (FA)
Fanconi Anemia, FA, is the most commonly diagnosed IBMFS
(Shimamura and Alter, 2010). It presents most commonly as pancytopenia with a
hypocellular bone marrow. Other diagnostic features include an increased MCV
(mean corpuscular volume) and increased HbF (fetal hemoglobin) (Ameziane et
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al., 2008; Soulier, 2011). More than 60% of patients have at least one congenital
anomaly; the most common of which is short stature followed by café au lait
spots, and hypo or hyperpigmentation. Approximately one third of patients have
radial defects involving the thumbs (Shimamura and Alter, 2010; Soulier, 2011).
The cancer risk for Fanconi Anemia patients is 50 times higher than the general
population, and the risk for MDS is increased 5,000 times. The most common
malignancies in order of incidence are AML, head and neck squamous cell
carcinoma, liver cancers, and vaginal squamous cell carcinoma (Rosenberg et
al., 2004; Rosenberg et al., 2005).
Thirteen genes have been identified as FA genes. With the exception of
FANCB, which is X-linked, the remainder are inherited in an autosomal recessive
fashion (FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG/
XRCC9, FANCJ, FANCJ/BACH1/BRIP1, FANCL, FANCM, FANCN/PALB2). All of
the FA linked genes are known to function in the repair of interstrand crosslinks in
DNA (Alter et al., 2007; Andreassen et al., 2004; Bakker et al., 2009; de Winter
and Joenje, 2009; Fagerlie et al., 2001; Meetei et al., 2003; Moldovan and
D'Andrea, 2009; Nakanishi et al., 2002; Pichierri et al., 2004; Singh et al., 2009;
Taniguchi et al., 2002; Wang, 2007; Wang et al., 2007). None of the Fanconi
genes are known to function in ribosome synthesis. Diagnostic criteria for FA
include testing of patient derived cells for extreme sensitivity to DNA crosslinking
agents, followed by sequencing of the known FA genes. Hematopoietic stem cell
transplant is the only curative therapy for this disease, though it only corrects the
anemia.
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Severe Congenital Neutropenia (SCN)
Severe congenital neutropenia patients are usually diagnosed due to an
infection, abscess, or pneumonia. The only defect associated with this illness
identified presently is a defect in the promyelocyte/myelocyte stage of
differentiation of neutrophil precursors. Multiple genes have been linked to SCN
but the two most commonly affected are ELA2 or ELANE genes. ELANE and
ELA2 encode neutrophil elastase enzymes which are the major secretory
proteins in neutrophils (Dale et al., 2006; Dale et al., 2000; Grenda et al., 2007).
The heterozygous mutations found associated with SCN are typically missense
mutations that interfere with protein folding in the endoplasmic reticulum.
Because the overall secretory load is so great in neutrophils and these proteins
represent such a high fraction of the total secretory pool, their misfolding causes
ER stress of such severity that maturation arrest occurs and cells undergo
apoptosis (Germeshausen et al., 2009a; Germeshausen et al., 2009b; Parikh
and Bessler, 2012; Skokowa et al., 2009; Tamary et al., 2010; Welte and Zeidler,
2009; Xia and Link, 2008; Zeidler et al., 2009). Treatment with G-CSF
(granulocyte-colony stimulating factor) or stem cell transplantation for patients
that don’t respond are the current standards of care for this disorder (Shimamura
and Alter, 2010).

Other Less Common IBMFS
Pearson syndrome (PS) is another IBMFS that is characterized by anemia
and exocrine pancreatic insufficiency, originally described in 1979 (Pearson et al.,
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1979). It is often fatal in infancy. Patients that survive past early neonatal life
develop symptoms similar to Kearns-Sayre Syndrome, which is a mitochondrial
myoencephalopathy (a disorder of muscle and brain tissues) (McShane et al.,
1991; Rotig et al., 1990; van den Ouweland et al., 2000). Patient samples were
found to have large deletions and/or rearrangements in mitochondrial DNA which
disrupt energy metabolism. This preferentially affects tissues requiring a high
threshold of mitochondrial function like the central nervous system and skeletal
muscle (Baerlocher et al., 1992; Blaw and Mize, 1990; Cormier et al., 1990;
Kleinle et al., 1997; Lee et al., 2007; Niaudet et al., 1994; Santorelli et al., 1996;
van den Ouweland et al., 2000).
The bone marrow failure and pancreatic insufficiency in Pearson
syndrome is reminiscent of SDS, but there are significant differences. Pearson
syndrome patients have a sideroblastic anemia. Ringed sideroblasts are
nucleated red cells that did not mature before leaving the bone marrow. They
produce a granular staining with dyes to visualize iron, because iron granules
form deposits in the mitochondria around the nucleus in these cells. This
perinuclear arrangement is what forms the ring of the ringed sideroblast.
Sideroblasts are also evident in X-linked sideroblastic anemia caused by defects
in the gene encoding δ-amino levulinic acid synthase. This enzyme is
mitochondrial and performs the first step in the synthesis of heme. The iron
deposits formed in this disease result from the lack of protoporphyrin IX
production. In the absence of protoporphyrin IX, iron that would normally be
used for heme synthesis deposits within the organelle giving rise to the ringed
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sideroblasts (Cotter et al., 1992; Cotter et al., 1994; Ferreira, 1993; Mantzourani
et al., 1995; Pagon and Bird, 1993; Pearson et al., 1979; Raskind et al., 1991;
Sutherland et al., 1988). Mitochondrial dysfunction in bone marrow progenitors
in Pearson’s syndrome presumably disrupts protoporphyrin IX synthesis,
explaining the sideroblasts seen in this disease. Also, SDS patients have a
hypocellular bone marrow and fatty infiltration of the pancreas, while Pearson
Syndrome patients usually have normocellular bone marrow with fatty
vacuolization (Blatt et al., 1994) and fibrotic changes in the pancreas
(Shimamura and Alter, 2010). In contrast, there are no reports of sideroblasts
associated with anemia in Shwachman Diamond syndrome patients. While
these observation emphasize the differences between Pearson Syndrome and
SDS, we feel that the work described in this dissertation indicates it may be
worthwhile to look more carefully at the relationship between these two disorders.
Amegakaryocytic thrombocytopenia (CAMT) is a deficiency of
megakaryocytes whose normal function is to produce platelets. Children usually
present with symptoms of a clotting disorder such as infants with excessive
bruising. It Is not uncommon for patients to be diagnosed as adolescents or
adults after development of a secondary condition such as aplastic anemia or
MDS without prior recognition of the initial deficit in megakaryocytes (Shimamura
and Alter, 2010). Biallelic mutations in the gene encoding the thrombopoietin
receptor, MPL, have been found in the majority of patients (Ihara et al., 1999). In
a knockout mouse model deficient in mpl it was discovered that the receptor, in
addition to its function in the production of megakaryocytes (Bartley et al., 1994;
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de Sauvage et al., 1994; Gurney et al., 1994; Kaushansky et al., 1994), is also
central to the maintenance of pluripotent bone marrow progenitors (Alexander et
al., 1996a; Alexander et al., 1996b).
Thrombocytopenia absent radii is another thrombocytopenia that differs
from CAMT because of the associated congenital defect in its title. These
patients lack radii bilaterally but still develop thumbs, though they are
nonfunctional (Thompson et al., 2001). This is an important distinguishing
characteristic from FA in which patients without radii always have associated
thumb defects (Shimamura and Alter, 2010).

Dissertation Overview
As a group, IBMFS show multifactorial pathophysiology with frequent links
to ribosome biology. Significant overlap in the clinical features of these disorders
tends to complicate diagnoses, making it difficult to differentiate one from another
based only on clinical parameters. Considerable insight into molecular
underpinnings of these diseases has been gained in recent years but many
questions remain unanswered. Further, this understanding at the molecular level
has not translated into dramatic improvements in diagnostic modalities, improved
treatments, or substantial improvements in various prognostic parameters. This
dissertation will focus on two specific IBFMS both of which arise to varying
extents from defects in ribosome synthesis. The first portion of this dissertation
will discuss the identification of a new ribosomal protein gene involved the
pathogenesis of DBA and provide a facile assay to screen patients for mutations
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in genes encoding large subunit ribosomal proteins. These studies also
investigate the putative molecular mediators responsible for the increased p53
activation shown in numerous DBA models.
The second portion of the dissertation will focus on SDS. It will include
descriptions of generation of a mammalian model for SDS in an erythroleukemic
human cell line and the functional consequences of depleting cells of SBDS. The
concepts envisioned in this chapter were the direct result of work performed in a
yeast model of SDS developed by Dr. Joseph Moore IV and Dr. Steve Ellis that
first identified the changes in respiration associated with loss of SDO1, the yeast
ortholog of SBDS. This part of the dissertation investigates a potential link
between changes in cellular metabolism and mitochondrial dysfunction in SDS
that has not been previously examined.
Given the heterogeneous nature of IBMFS several methods of
investigation were initially pursued before the particular methods used in the
body of the dissertation were chosen. Those portions of my laboratory work not
contained within the body of the text are located in appendix one. This includes
previously published work on an inducible shRNA mouse model that led to
decreased RPS19 protein expression and is arguably the most phenotypically
accurate animal model for DBA developed to date (Jaako et al., 2011) as well as
additional work in the mES cell model introduced in chapter three that did not
easily fit within the description of the mechanisms described in that chapter.
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CHAPTER II
MATERIALS AND METHODS

Human Sample Preparation
All human samples were collected using protocols necessary for the
protection of human subjects and in compliance with institutional guidelines.
Whole blood samples (ranging in volume from 1.5-8 ml) were collected by
personnel at the patient’s representative institution in vacutainer tubes treated
with sodium heparin to prevent clotting. The samples were then catalogued and
shipped to the University of Louisville devoid of identifying patient characteristics.
Initial experiments were performed on samples from the proband, her unaffected
parents, and a healthy volunteer all of which were collected at Loma Linda
University. Subsequent samples including patients with characterized RPL5 and
RPL35A mutations were obtained from Dr. Adrianna Vlachos at the Feinstein
Institute for Medical Research in New York and Dr. Jason Farrar at Johns
Hopkins University, respectively.

Buffy Coat Preparation of Mononuclear Cells and Stimulation with ConA
All samples involving human blood were treated as potentially hazardous
materials and necessary precautions were taken. All centrifugation steps were
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carried out at room temperature. Whole blood was removed from vacutainer
tubes and placed in sterile 50 ml conical tubes. The blood was then diluted with
an equal volume of sterile PBS (Mediatech, VWR). Three ml of Ficoll reagent
(GE Healthcare) was added to the bottom of 15 ml conical tubes and 4 ml of
diluted blood carefully layered onto the Ficoll at an angle to prepare an
appropriate interface and maximize cell separation. Aliquots of each sample
were centrifuged at 400 x g for 40 minutes with the acceleration set to 1 and the
brake set to 0. All but 1 ml of the serum layer on the top of the gradient was
aspirated with a 5 ml pipette and then the buffy coat (white fluffy phase)
containing mononuclear cells was collected very carefully and slowly to avoid
contamination of the buffy coat with other cellular layers. The resulting buffy coat
was placed in a fresh 15 ml sterile conical tube and resuspended in a total
volume of 14 ml with sterile PBS. An aliquot was taken from this solution for
counting in a 1:1 solution with trypan blue (MP Biomedicals) in a hemocytometer
(Hausser Scientific) to determine cell numbers in each sample.
The cells were harvested by centrifugation at 1500 rpm for 10 minutes and
then suspended in RPMI-C. RPMI-C was generated from RPMI 1640
(Mediatech, VWR) with the addition of 10% FBS (Mediatech-VWR, heat
inactivated), 50 U/ml penicillin (Invitrogen), 50 µg/ml streptomycin (Invitrogen),
0.01M HEPES pH 7.4 (Invitrogen), and 2 mM L-glutamine (GlutamaxInvitrogen). Immediately before use, concanavalin A (ConA), was added to a
final concentration of 5 µg/ml (Sigma Aldrich, prepared as a stock in RPMI at 5
mg/ml, stored at -20oC, and diluted 1:1000 for use). Cells were diluted to a

36

concentration of 2x106 cells/ml. Cells were stimulated with ConA for 96 hours at
37oC with 5% CO2 in air in a humidified atmosphere. After 96 hours cells were
harvested using QIAshredder columns to lyse cells and remove cell debris. An
AllPrep kit from QIAgen was used for the extraction of RNA, DNA, and protein
from the samples. The manufacturer’s instructions were followed with the
following modifications: fresh β-mercaptoethanol was added with each cell
preparation rather than adding to the stock solution, RNA was eluted in a final
volume of 30 µl and DNA was eluted in a final volume of 100 µl.

Northern Blotting
RNA was quantified using the Take3 Synergy plate-reader system (Applied
Biosystems) and equal amounts of RNA were fractionated by electrophoresis on
1.5% formaldehyde-agarose gels as previously described (Flygare et al., 2007).
Typically, 5-10 µg of total RNA in a final volume of 9 µl of diethylpyrocarbonatetreated (1%) water, was mixed with 33 µl of RNA sample buffer: 1.2 X MOPS
(10X MOPS; 0.4M 3-(N-morpholino) propane-sulfonic acid, 100 mM sodium
acetate, and 10 mM EDTA adjusted to pH 7 with sodium hydroxide), 7.9%
formaldehyde, 60% formamide, and 0.06 mg/ml ethidium bromide. After mixing
the samples were heated to 65° for 15 minutes and 4 µl RNA dye (50% glycerol,
1 mM EDTA, 0.4 % bromphenol blue, 0.4 % xylene cyanol) was added. RNA
fractionated in this manner stains with ethidium bromide in the sample buffer so
there is no need for subsequent staining of gels after separation. Gel images
were captured by a Bio-Doc-It Imaging System. RNA was subsequently
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transferred to zeta-probe (BioRad), washed in 2x SSC (20X SSC: 3M NaCl, 0.3M
NaCitrate pH 7.4) and 1%SDS (prepared as a 10% w/v solution with powder from
Fisher) for 4 or more hours at 55°C and prehybridized overnight at 37° in Ambion
ULTRAhyb oligo hybridization buffer. Membranes were hybridized overnight with
radiolabeled probes shown in Table 1. Membranes were subsequently washed
with 6 X SSC at 37° and placed in phosphorimager cassettes for image capture
using typhoon imaging software and band intensity quantified using Imagequant
software (GE Healthcare).
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Probe Hybridization
name
location
18SE

5’18SITS1 5’

5.8SITS2

3’ 5.8SITS2 5’

ITS2b

ITS2

ITS2 d/e ITS2

5S

5S

5.8S

5.8S

18S

18S

RP mutation and
Processing Defect
(Citation)
RPS19

Sequence
(H=human, M=mouse)
M: 5’ CAG GCC GCC GCT CCT CCA
CAG TCT C 3’

increased 21S (Flygare et
al., 2007)
H: 5’ CCT CGC CCT CCG GGC TCC
GTT AAT GAT C 3’
RPL5, RPL11
M: 5’ GAC GCG ATT GAT CGT CAA
CCG ACG CT 3’
increased 32S and 12S
(Rouquette et al., 2005)
H: 5’ GGG GCG ATT GAT CGG CAA
GCG ACG C 3’
RPL5, RPL11
M: 5’ CTG CGA CGC AAC TCC CAG
CCG CGC A 3’
increased 32S and 12S
(Gazda et al., 2008)
H: 5’ CTG CGA GGG AAC CCC CAG
CCG CGC A 3’
RPL5, RPL11
H 5’ GCG CGA CGG ACG ACA CCG
CGG 3’
increased 32S and 12S
(Gazda et al., 2008)
Mature rRNA
H: 5’ CAG ACG AGA TCG GGC GCG
(Choesmel et al., 2007;
TTC 3’
Rouquette et al., 2005)
M: Used human probe
Mature rRNA
H: 5’ CAA TGT GTC CTG CAA TTC AC
(Choesmel et al., 2007;
3’
Rouquette et al., 2005)
M: Used human probe
Mature rRNA
H: 5’ GCA TGG CTT AAT CTT TGA
(Choesmel et al., 2007;
GAC AAG CA 3’
Rouquette et al., 2005)
M: used human probe

!!
Table 1: Northern blot probes used for the identification of pre-rRNA
processing intermediates and mature rRNAs
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Cell Culture and Cytokines
All mammalian cell lines were cultured at 37oC with 5% CO2 in a
humidified atmosphere.

TF-1 DBA Model
The TF-1 erythroleukemic cell lines were maintained in RPMI 1640
(Mediatech) supplemented with 10% heat inactivated fetal bovine serum (FBS),
(Mediatech), 1% P/S, (Invitrogen) and 5 ng/ml GM-CSF (Peprotech). The TF-1
cell line with a doxycycline inducible shRNA targeting RPS19 mRNA was
developed in the Karlsson laboratory as previously described (Miyake et al.,
2005). Doxycycline (Sigma Aldrich) was added to cultures at a final
concentration of 5 ng/ml for four to seven days before cells were harvested for
subsequent experiments.

TF-1 SBDS Model
The TF-1 erythroleukemic cell lines were maintained in RPMI 1640
(Mediatech) supplemented with 10% heat inactivated fetal bovine serum
(Mediatech), FBS, 1% penicillin/streptomycin, P/S, (Invitrogen) and 5 ng/ml
GMCSF (Peprotech). TF-1 cell lines transduced with lentiviral vectors (Sigma
Aldrich) targeting SBDS mRNA were developed by Gulay Sezgin in the
laboratory of Dr. Johnson Liu. Briefly, TF-1 cells were transduced at a cell
density of 1x106 cells with lentiviral particles [(200 µl of 107 TU/ml) purchased
from Sigma Aldrich] using 6µg/ml polybrene.
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Sequences included in the lentiviruses targeting SBDS are:
#1: 5′ - CCGGGCCAAATACTTGCTTAAACTACTCGAGTAGTTTAAGCAAGTAT
TTGGCTTTTTG - 3′
#2: 5′ - CCGGGCCAACAGTTAGAAATCGTATCTCGAGATACGATTTCTAACTG
TTGGCTTTTTG - 3′

To establish stable cell lines, transduced TF-1 cells were placed under
puromycin selection at 5 µg/ml (Fisher). Multiple clones for each of the two
shRNA sequences used to reduce SBDS expression were established.

Mouse Embryonic Stem Cell Models of DBA
Mouse embryonic stem cell (mES) lines where one of two known DBA
genes were inactivated by gene trap technology were purchased commercially.
Two sets of cell lines with haploinsufficiency for Rps19 were obtained from the
Mutant Mouse Regional Resource (MMRR) and one cell line mimicking
haploinsufficiency for Rpl5 was obtained from the German Gene Trap
Consortium. A parental control cell line was also obtained for each gene trap.
The S17-10H1 cell line was generated from the AK7.1 mouse embryonic stem
cell parental line by electroporation of the ROSAFRY gene trap retroviral
construct in intron 2 of a single copy of Rps19 (Fig. 3). A “rescue vector” to
restore Rps19 protein expression was generated by inserting the Rps19 cDNA
sequence into the pCMV6-A-Puro expression vector (Origene). This rescue
plasmid called ORF-S17 was electroporated into the mES cells (Bio-Rad Gene
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Pulser). An empty vector control cell line was created in the same fashion. The
cell line heterozygous for Rps19 transfected with the empty vector is called
“EMT-S17.” This cell line should mimic Rps19 haploinsufficiency observed in
DBA patients. Cells with the rescue vector “ORF-S17” should mimic healthy
controls. Both cell lines express a gene for puromycin resistance.

42

Fig. 3: Insertion of the ROSAFARY gene trap vector between exon 2 and
exon 3 of Rps19 gene created the S17 gene trap cell line.
The ROSAFARY gene trap vector was used to create a genetrap library that has
one gene in each cell line that is interrupted by this retrovirus. The AK7 mouse
parental line has the inserted retroviral sequence located between exons two and
three of the Rps19 gene, leading to two fusion genes. The first fusion gene is
referred to as a promoter trap and creates a fusion gene between the gene being
disrupted and the β-geo gene coding for neomycin resistance. Transcription is
halted downstream of β-geo by a poly(A) addition sequence. Since this fusion
gene expresses only exons 1 and 2 of Rps19 it is unlikely to lead to a functional
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product. The second fusion gene links the hyg gene, a selection marker, to
exons 3-6 of Rps19. Again, this fusion gene is unlikely to produce a functional
Rps19 protein.
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The second Rps19 gene trap model, termed YHC074, was also purchased
from MMRC and was generated using the parental mES cell line E14Tg2a.4.
The pGT0lxf gene trap vector in this cell line is inserted into intron 3, between
exon 3 and 4 of the Rps19 gene (Fig. 4). The third mES gene trap cell line,
D050B12, was purchased from the German Gene Trap Consortium and was
generated from the parental TBV-2 mES cell line. This cell line was created
using the ROSAFRY gene trap vector inserted into intron 3 of the Rpl5 gene (Fig.
4).
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Fig. 4: Location of gene trap insertions in mES cell lines used.
The S17 cell line contains the insertion between exons two and three of Rps19.
The YHC074 cell line contains a gene trap insertion in between exons three and
four of Rps19. The D050 cell line contains a gene trap insertion in between
exons three and four of the Rpl5 gene. (Gene trap technology is described in
greater detail in the legend of Fig. 3).
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Mouse embryonic stem cells were cultured under the conditions
established by stem cell technologies (www.stemcell.com). Tissue culture dishes
were coated by adding an excess of 0.1% gelatin solution from Stem Cell
Technologies (3 mL for a T25 flask, with proportional increases depending on
dish size), allowing the plate to sit at room temperature in the biosafety cabinet
for 20 minutes, removing excess gelatin, and allowing the plates to dry before
use. Maintenance media was prepared using DMEM high glucose (Invitrogen)
supplemented with 15% stem cell grade FBS (Stem Cell Technologies), 100 µM
non-essential amino acids (Stem Cell Technologies), 100 U/ml penicillin, 10 µg/
ml streptomycin (Invitrogen), 2 mM glutamine (Glutamax ©Invitrogen) 100 µM
monothioglycerol (MTG; Sigma), and 10 ng/ml mouse leukemia inhibitory factor
(mLIF; Stem Cell Technologies). A stock solution of mLIF was made fresh on the
day of media preparation by diluting 1:100 in DMEM and adding 43 µL to each 50
ml aliquot of media. Media was sterile filtered prior to addition of mLIF and was
kept for no more than one week at 4oC. The TBV-2 and its derived line,
D050B12, were originally maintained on an embryonic fibroblast feeder layer
(Stem Cell Technologies) in the presence of mitomycin C (Sigma) before being
plated on gelatin coated plates without fibroblasts to develop feeder independent
cell lines. All experiments were performed on feeder independent cell lines. The
other two sets of mES cells were always plated without feeders on gelatin coated
tissue culture dishes.
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Animal Models
Inducible Rps19 knockdown
All animals were maintained at Lund University, Sweden by the laboratory
of Stefan Karlsson. Tssues and cell lines were shipped to the University of
Louisville for further study. Briefly, embryos were developed with one or two
copies of either sequence “B” or sequence “D” shRNA designed to target Rps19
mRNA under the control of a tet-on promoter located in the collagen A1 locus
(Jaako et al., 2011). Animals with single copies of the inducible shRNA (B/+ or D/
+) were termed “single dox,” and those with two copies of the inducible shRNA
(B/B or D/D) were demarcated as “double dox.” Liver and bone marrow samples
from mice given doxycycline in their drinking water for two weeks were sacrificed
and used for the experiments outlined below.
Mouse embryonic fibroblasts (MEF) from the Karlsson mice were
maintained in DMEM media (Mediatech), supplemented with 10% FBS
(Mediatech), and 1% P/S (Invitrogen). To decrease Rps19 expression,
doxycycline (Sigma Aldrich) was added to a final concentration of 1 µg/ml or 5
µg/ml for seven to fourteen days before sample harvest (Jaako et al., 2011).

Cell Viability and Rescue with NAC
Cell counts were performed by taking an aliquot of cells and diluting with
an equal volume of Trypan Blue (MP Biomedicals) and adding 10 µL of the
resulting solution to a hemocytometer (Hausser Scientific) to determine cell
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number. All viability experiments were performed in triplicate with three separate
counts obtained for each experiment.
After four days of growth, the cell cultures were treated with various
concentrations of N-acetyl cysteine (Sigma). The stock solution of 500 mM was
prepared in RPMI media and dilutions made to a final concentration of 50 µM,
100 µM, 500 µM, and 1 mM when added to cultures at day four. After 24 hours
of treatment the cultures were counted as described above and used for cell
cycle experiments as delineated in the flow cytometry section.

Polysome Profiling
Cells grown in culture were treated with a 1/100 vol of 9 mg/ml
cycloheximide (Sigma) for 10 minutes at 37oC. All solutions used in harvesting
polysome samples In subsequent steps also contianed the same concentration
of cycloheximide. Cells were trypsinized (0.25% Trypsin EDTA, Invitrogen) when
appropriate, or pelleted by centrifugation at 800 x g for 5 minutes. Cells were
washed with cold PBS (VWR), and lysed using a handheld homogenizer (Fisher)
in polysome buffer containing 50 mM Tris-HCl pH 7.5 (Fisher BP152-1, prepared
with DEPC treated water as a 1M stock solution and titrated to pH 7.5 with
concentrated HCl), 240 mM NaCl (Fisher S271-1 prepared with DEPC treated
water as a stock solution of 2 M), 10 mM MgCl2 (Sigma M1028), 5 mM βmercaptoethanol (Sigma), 250 mM Sucrose (Fisher BP220-212), 2% Triton X
(Sigma), 100 µg/ml heparin (Alfa Aesar), and 90 µg/ml cyclohexamide (SigmaC7698). Debris was pelleted in a refrigerated microcentrifuge (Eppendorf) at
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8000 x g for 10 minutes and the RNA concentration of the supernatant
determined using a Nanodrop (Thermo Scientific). Equal quantities of total RNA
in a maximum volume of 350 µL were added to the top of 15-55% sucrose
gradients. Gradients were poured using a bone marrow biopsy needle into
RNAse/DNAse free round bottom polyallomer 17 mL tubes (#5042) from Seton
Scientific with 3 mL layers of 15% (w/v), 25%, 35%, 45%, and 55% sucrose
(Fisher BP220-212) containing 25 mM pH 7.5 Tris-HCl (Fisher: BP152-1,
prepared with DEPC treated water as a 1 M stock solution and titrated to pH 7.5
with concentrated HCL) 25 mM NaCl (Fisher S271-1 prepared with DEPC
treated water as a stock solution of 2 M) and 5 mM MgCl2 (Sigma M1028, stock
solution). Gradients were centrifuged at 28,000 rpm in a SW 28 rotor for 7-12
hours using a Beckman L8-M ultracentrifuge. The gradient fractions were then
collected using an ISCO density gradient fractionator (Model 185), retriever
(Retriever 500), and flourinert (Sigma) and visualized using a UA-6 UV/Vis
detector (ISCO), and type 11 optical unit with filters corresponding to 254nm
(ISCO) (Jaako et al., 2011).
Western Blotting
Cell pellets were harvested and lysed by snap freezing in RIPA buffer
containing leupeptin, aprotinin, PMSF, and protease inhibitor cocktail (Sigma).
Cell debris were pelleted by centrifugation at 5,000 x g in a refrigerated
microcentrifuge (Eppendorf). Protein concentration was determined using the
BCA method (Thermo Fisher) and equal concentrations of protein were
suspended in Nupage buffer (Invitrogen) containing dithiothreitol ( 50mM DTT;
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Sigma). SDS-PAGE was performed using 2.5 µg to 10 µg of protein and 4-12%
Bis-Tris Ready gels (Invitrogen) with protein size estimated by Biorad dual color
standards. After transferring proteins to nitrocellulose membranes (BioRad) in
transfer buffer containing 20% methanol (Fisher) overnight at a constant 20 Volts
at 4oC (BioRad transfer apparatus), membranes were blocked with 5% milk in
TBST (Fisher) and immunoblotting was performed using the following antibodies:
anti-RPS19 (H00006223-M01, Abnova; 1:1,000), anti-RPL5 (ab74744, Abcam;
1:500-1:1000), anti-p53 (9282, Cell Signaling; 1:1000-1:2000), anti-RNA
Polymerase II p.14.5 (abs8436, Abcam; 1:2,000), anti-LDH-A (SC27230, Santa
Cruz; 1:1,000), anti-VDAC1 (4661, Cell Signaling; 1:1,000), anti-cytochrome c
(SC-7159 Santa Cruz; 1:1,000), anti-Tom20 (a custom antibodyreceived as a
generous gift from Dr. Brian Wattenberg1:500), anti-pyruvate dehydrogenase,
PDH, (SC-65242, Santa Cruz, 1:1,000), anti-superoxide dismutase 2, SOD2,
mitochondrial (SC-20080, Santa Cruz, 1:1,000), anti-Tom40 (SC-11414, Santa
Cruz, 1:1,000), anti-isocitrate dehydrogenase 3α, IDH3α, (AP1927a, Abgent,
1:1,000), anti-IDH2 (H00003418-A01, Novus biological supplied by Abnova,
1:1,000), anti-β tubulin (ab6046, Abcam, 1:1,000) and anti-β-actin (SC69879
AC-15 Santa Cruz; 1:5,000). Secondary antibodies used were either goat antimouse (#3430 Thermo Scientific and Santa Cruz), goat anti-rabbit (7074, Cell
signaling technology), or donkey anit-goat (SC2020, Santa Cruz) as dictated by
the primary antibody. The resulting complexes were detected using
chemiluminescent reagents and protocols from Pierce Chemical, GE Healthcare,
or Thermo Scientific.
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Flow cytometry
Cell Cycle Analysis
To analyze the relative amounts of cells in different phases of the cell cycle
in asychronized cultures, 1×106 TF-1 cells expressing lentiviral vectors targeting
SBDS mRNA or scrambled controls were harvested and washed with PBS. Cells
were fixed in 70% ethanol for at least 30 min at -20o C and washed twice with
PBS. After resuspension in 1 ml of PBS, cells were treated with ribonuclease at
100 µg/ml (RNAse A, Qiagen, MD). Propidium iodide was added to a final
concentration of 50 µg/ml (Invitrogen), and samples were analyzed with a BD
FACS Calibur (BD Biosciences, San Jose, CA) cytometer. The events were gated
to remove both debris and doublets (signals generated by clumps of two or more
cells) and 20,00-50,000 total events were used for subsequent analyses. The
FL3H-PI channel was used for data collection. The resulting histograms were
analyzed using FlowJo software and the Dean/Jett/Fox method used to quantify
phases of the cell cycle (Treestar Ashland, OR) (Dempster A, 1977; Fox, 1980;
Krishan, 1975; S, 1997; Shapiro, 2003; Watson et al., 1987; Webb, 2002).

JC-1 Mitochondrial Membrane Potential Assay
Mitochondrial membrane potential was assessed using the JC-1 Assay kit
from Molecular Probes according to the manufacturer’s instructions. This assay
measures mitochondrial membrane potential irrespective of mitochondrial size or
density. The JC-1 compound ((5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide) shows a shift in emission spectrum from green (529
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nm) when the dye is outside of mitochondria to red (590 nm) as the dye enters
mitochondria in a membrane potential-dependent manner and forms aggregates
that are no longer able to leave the mitochondria. Pretreatment with 50 mM
CCCP, an uncoupler which dissipates the proton gradient, prevents the
accumulation of JC-1 in mitochondria and served as a negative control.
Unstained cells served as a control for cellular autofluorescence. After
incubation with the JC-1 compound for 20 minutes at 37oC, cells were harvested
and suspended in PBS for analysis with a BD FACS Calibur (BD Biosciences)
cytometer. A dot plot of side scatter (SSC) and forward scatter (FSC) was used
to determine the gating of the appropriate population of live cells and to remove
debris. At this point any extracellular JC-1 that wasn’t removed as cells were
harvested and washed was also eliminated.
The following strategy was employed to analyze the membrane potential
data generated by flow cytometry. The FL2 channel was used to measure red
fluorescence and is graphically represented on the y-axis and the FL-1 channel
was used to measure green fluorescence which is graphed on the x-axis.
Quadrants were created in the plot to capture different cell populations. The
lower left quadrant represents auto-fluorescence and was defined by unstained
control samples. The upper right quadrant includes cells expressing high levels
of green and red fluorescence and represents the mitochondrial potential of
control TF-1 cells. The lower right quadrant represents cells with relatively high
green fluorescence but low red fluorescence as would be expected if the
membrane potential was decreased (Chaoui et al., 2006; Chazotte, 2011;
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Cossarizza and Salvioli, 2001; Garner and Thomas, 1999; Guthrie and Welch,
2008; Keil et al., 2011; Legrand et al., 2001; Lugli et al., 2007; Reers et al., 1995;
Salvioli et al., 1997; Simeonova et al., 2004; Smiley et al., 1991). A minimum of
40,000 events were collected for each sample replicate. Analyses were
performed using FlowJo software from Treestar to perform appropriate
compensation, gating, and comparison of all replicate data using the same
parameters.

Annexin V/ Propidium Iodide Assay of Apoptosis
Flow cytometry was also employed to study apoptosis in our cell lines.
Cells were stained with annexin and propidium iodide (PI) prior to evaluation by
flow cytometry. An Annexin V-FITC/PI kit was purchased from E-Biosciences and
experiments performed according to the manufacturer’s instructions. The
annexin V stain recognizes outer membrane phosphatidylserine molecules
whose hydrophilic head flips from the inner to the outer membrane during early
phases of apoptosis. Co-staining with PI allows one to exclude cells from the
analysis whose membranes are no longer intact, as PI stains the DNA/RNA
species of necrotic cells or those in the later stages of apoptosis. The samples
were analyzed using the BD FACS Calibur (BD Biosciences) with a minimum of
40,000 events collected. The samples were gated using an unstained control
sample as well as single-stained controls treated with only PI or annexin-V. The
data collected were then analyzed using FlowJo software (Treestar). Data were
plotted with FL3-PI on the Y-axis and FL1-H: annexin V on the X axis. As before,
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the lower left quadrant represents autofluorescence, as was delineated using
unstained control samples. Cells staining highly for both PI and Annexin-V were
then found in the top right corner. These samples were labeled as “late
apoptosis.” Those samples contained in the lower right corner, staining highly for
Annexin-V only were considered “early apoptotic” cells. The percentage of
events contained within each of the quadrants was then calculated.

Reactive oxygen species
Reactive oxygen species were measured using 2',7'-dichlorfluoresceindiacetate (DCFH-DA). DCFH-DA is rapidly converted to the non-fluorescent
compound DCFH once inside cells by cellular esterases. In the presence of
ROS cellular peroxidases convert DCFH to DCF which is highly fluorescent.
Measurement of DCF fluorescence thereby provides a measure of cellular ROS.
This assay for detecting ROS was modified from previously published work
(Ambekar et al., 2010). Viable TF-1 cells were counted using Trypan blue
exclusion and plated in 96 well plates (Costar) at a density of 1x105 cells/well. A
minimum of three replicates was used for each sample including control treated
with DMSO and CCCP. DCFH-DA (Sigma) suspended in DMSO (Sigma) was
added to wells to a final concentration of 20 µM. After incubation at 37o for 15
minutes the plates were then read once every minute using filters appropriate for
an excitation wavelength of 505 nm and emission at 529 nm using the Synergy
plate reader (Biotek). After subtracting the intensity of the blank (DMSO), values
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for three replicate experiments are represented as a ratio of fluorescence
intensity with SBDS knockdown relative to scrambled controls.

Oxygen consumption
Oxygen consumption was measured using a Gilson oxygraph with a
Clark-type electrode following previously published protocols (Campian et al.,
2007; Gao et al., 2010). Cells were suspended in 550 µl of growth media at a
concentration of 2.7 x 106 cells/ml and placed in the chamber. Basal respiration
tracings of oxygen consumption were monitored for two minutes. Carbonyl
cyanide m-chlorophenyl hydrazine, CCCP (Sigma), was added to the chamber
using a Hamilton Syringe to a final concentration of 10 mM to measure maximal
respiration rates of each sample for eight additional minutes. Respiration rates
were expressed as µmol of oxygen consumed per million cells per minute.
Linear portions of the curves were then used to express respiration rates in terms
of the basal respiration rate relative to the maximal respiration rate.

Statistical Analysis
All data are presented as the result of no less than three independent
experiments. Microsoft’s Excel program and Graphpad’s Prism software were
used to perform all statistical analyses of replicate data. When appropriate an
unpaired Student’s t-test was used to determine the significance of differences
between sample means. ANOVA statistical analyses were run when indicated by
sample demographics and the appropriate post-hoc tests used based on sample
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parameters. Unless otherwise stated, bar graphs represent the mean of all
experimental replicates using the standard deviation for error bars and asterisks
represent p-values as such: *p<0.05, **p<0.01, ***p<0.005.
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CHAPTER III
THE VITAL ROLE OF PRE-RRNA PROCESSING IN DBA DIAGNOSIS
AND GENE DISCOVERY

Introduction
Diamond Blackfan Anemia, (DBA), was first linked to a mutation in the
gene encoding a ribosomal protein, RPS19, in 1999. Since then, causative
mutations have been indentified in 10 genes that encode protein components of
both small and large ribosomal subunits (Ball, 2011; Draptchinskaia et al., 1999).
Despite this progress, the genes affected in many patients have not been
identified using DNA sequence analysis of candidate ribosomal protein genes.
Current genome-wide efforts have been able to identify patients with large
deletions including known ribosomal protein genes that were not picked up by
DNA sequencing. Still, the underlying genetic defect is still unknown in
approximately 40% of DBA patients (Boria et al., 2010; Farrar et al., 2011).
Pre-rRNA processing experiments have played a critical role in gene
discovery efforts in DBA, linking mutations in prospective genes to defects in
ribosome synthesis (Campagnoli et al., 2008; Choesmel et al., 2008; Farrar et
al., 2008; Flygare et al., 2007; Robledo et al., 2008; Rouquette et al., 2005). The
role of pre-rRNA processing in gene discovery has become even more critical as
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whole genome approaches have been applied to identifying new DBA genes
whose potential role in ribosome synthesis is potentially more tenuous than that
for ribosomal protein genes. The work described in this chapter illustrates the
contribution pre-RNA processing studies can make to diagnosing DBA in
challenging clinical cases and in discovering new genes beginning with the
description of a particularly challenging case. An outgrowth of these studies is
the identification of a new strategy for tracking pre-rRNA processing defects
associated with genes encoding large subunit ribosomal proteins. We feel that it
should be possible for clinical laboratories to develop this approach as a new
diagnostic tool for DBA. Finally, these studies highlight ribosomal proteins RPL5
and RPL11 as playing a unique role in DBA pathophysiology based on their
interaction with 5S rRNA and the distinctive role of the RPL5/RPL11/5S rRNA
complex both in ribosome biogenesis and signaling ribosome stress.
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Case Report
A child presented to a physician in the San Diego area at four months of
age with a severe macrocytic anemia. She also had neutropenia and elevated
numbers of morphologically normal platelets, which does not fit the classical
criteria for DBA. She could however potentially fall under a broader diagnostic
heading of non-classical DNA. Non-classical DBA includes patients exhibiting
effects on myeloid lineages other than erythrocytes (Boria et al., 2010; Farrar et
al., 2011; Vlachos et al., 2008). In addition to her hematopathology, the proband
had multiple congenital anomalies including bilateral fusion of the radius and
ulna. Both of her thumbs showed aberrations in development that were not
symmetrical. One hand contained a triphalangeal thumb and the other was
hypoplastic. Bone marrow biopsy revealed a paucity of erythroid precursors and
a block in maturation of granulocyte precursors that would normally differentiate
into neutrophils, and a normal female (46XX) karyotype. Given the lack of a
clear diagnosis based on the patient’s clinical profile, molecular studies analyzing
the possible involvement of multiple inherited bone marrow failure syndromes
(IBMFS) were performed.
The litany of laboratory tests that ensued began with analyses of defects
associated with the most common IBMFS, Fanconi Anemia (FA) (Shimamura and
Alter, 2010). Fanconi anemia results from defects in DNA repair and patient
lymphoblasts were tested for their sensitivity to DNA crosslinking agents, a
routine test for this disease (Shimamura and Alter, 2010). These tests were
negative. Shwachman Diamond syndrome was also considered unlikely as no
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pathogenic mutations were found in the SBDS gene, which is affected in over
90% of SDS patients (Dror and Freedman, 1999, 2002; Johnson and Ellis, 2011;
Nihrane et al., 2009; Tsangaris et al., 2011; Yamaguchi et al., 2011). Tests were
also performed on the eleven ribosomal protein genes known to be involved in
DBA. While two single nucleotide polymorphisms were found, one each in
RPS19 and RPL11, these changes were unlikely to be deleterious.
Our collaborators then turned to comparative genomic hybridization
(CGH), a technique for scanning the entire genome for copy number variations.
CGH on this patient revealed a 3.2 megabase deletion on chromosome 2 at
2q11.2. This result was confirmed by fluorescence in situ hybridization. Further,
as neither parent exhibited this deletion it was presumed to have arisen
spontaneously in the child. The deletion at 2q11.2 observed in this child includes
a number of genes including RPL31, which encodes a ribosomal protein of the
60S subunit. This suggested the child could be haploinsufficient for RPL31,
which would be consistent with a diagnosis of Diamond Blackfan anemia.
However, as RPL31 has not been identified as a DBA gene previously, we felt it
was important to address whether the 2q11.2 deletion was associated with a
defect in ribosome biogenesis in this patient.
To address whether this child had a defect in ribosome biogenesis, we
employed a protocol we recently developed as part of a consortium of
investigators studying the molecular basis of DBA. This protocol involves the
isolation of mononuclear cells from peripheral blood, followed by culturing and
activating T lymphocytes with concanavalin A (ConA) (Farrar et al., 2011). Total
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RNA isolated from these cells is then used for pre-rRNA processing studies. This
technique has so far revealed robust and reproducible pre-rRNA processing
defects in many DBA patients.
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Results

Pre-rRNA processing defects associated with haploinsufficiency for RPL31
Fig. 5A shows an ethidium bromide stained RNA samples in a
formaldehdye gel of samples obtained from the index proband from San Diego.
The samples were sent to us blinded, and the codes revealed only after preRNA processing studies were completed and data analyzed. Samples included
the proband, her unaffected parents, and an unrelated healthy control. Even at
the level of ethidium bromide visualization with UV, it was clear one of the four
samples stood out from the others. Sample 06518 has a prominent band above
that of 28S rRNA, later shown by hybridization to be 32S pre-rRNA (Fig. 5B and
Fig 6). Subsequent decoding of the samples revealed that 06518, was in fact
derived from the proband. As shown in Fig. 1, 32S pre-rRNA contains both 5.8S
and 28S mature RNAs separated by an intervening sequence labeled ITS2.
Cleavages within ITS2 ultimately give rise to the 3′ end of 5.8S RNA and the 5′
end of 28S RNA. The pre-RNA processing defect in this sample is specific for
RNA components of the large subunit as would be expected for RPL31, a large
subunit ribosomal protein.
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Fig 5: Pre-rRNA processing defect associated with haploinsufficiency for
RPL31
Total RNA from blood mononuclear cells cultured for 96 hours in the presence of
ConA was isolated and separated on 1.5% formaldehyde agarose gels. Sample
codes and RPL31 gene status are listed below each duplicated sample. (A) RNA
gel of ethidium bromide stained samples (B) RNA was transferred to zeta-probe
and hybridized with probe ITS2b (Sequence in Table 1). The pre-rRNA labeled
32S pre-rRNA was confirmed using a number of different oligonucleotides for
hybridization to demarcate its boundaries in both this gel (Fig 6) and in a gel with
other DBA patient samples shown in Fig 7 and 8.
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Fig 6: Northern blot of RNA isolated from the index proband, unaffected
parents, and a healthy control reveals a processing defect in proband prerRNA
(A) Northern blot of the gel shown in Fig. 5 after probing with an oligonucleotide
complementary to sequences bridging the 3′ end of 5.8S rRNA and the 5′ end of
ITS2. (B) The membrane in A was stripped and probed with an oligonucleotide
complementary to mature 5.8S rRNA. The pre-rRNA and rRNA species are
labeled to the right of the northern blots and the patient number and genotype
shown below. All samples were run in duplicate.
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A common pre-rRNA processing signature in patients haploinsufficient for large
subunit ribosomal proteins
To compare the pre-RNA processing defect associated with RPL31
haploinsufficiency with that for haploinsufficiency of other large subunit ribosomal
proteins, we analyzed samples from patients with mutations in either RPL5 or
RPL35A, two known DBA genes encoding large subunit proteins (Farrar et al.,
2008; Gazda et al., 2008). Fig. 7A shows an ethidium bromide-stained gel of the
different patient samples together with an unaffected parent of the RPL31 patient.
Here again, a prominent band just above the 28S rRNA is evident in the patient
samples, but is present in much lower amounts in the healthy controls. Fig. 7B
shows this band is 32S pre-rRNA. Thus, it would appear from each of the DBA
samples we have tested where a large subunit ribosomal protein gene is
responsible for the disease, there is a clear increase in 32S pre-RNA evident at
the level of ethidium bromide staining. A similar sized band has been observed
in RNA gels of patients with mutations in RPL11 (Elisa Pavesi, University Eastern
Piemonte, Novara Italy, personal communication) indicating that an increase in
32S pre-rRNA may be a common characteristic of deficiencies of large subunit
ribosomal proteins. Given that this increase can be visualized by gel
electrophoresis and ethidium bromide staining, the increase in 32S pre-rRNA
may be developed as a diagnostic tool for DBA when genes encoding large
subunit ribosomal proteins are suspected.
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Fig 7: Evidence of a common pre-rRNA processing signature associated
with haploinsufficiency for large subunit ribosomal proteins.
(A) Total RNA was prepared from peripheral mononuclear cells cultured for 96
hours in the presence of ConA. RNA was fractionated on 1.5% formaldehyde
agarose gels and stained with ethidium bromide. Affected genes in patient
samples are listed above each lane. When a gene is listed twice this denotes
duplicated samples from the same patient. The healthy control is denoted as Wt.
(B) RNA was transferred to a zeta-probe membrane and hybridized with
oligonucleotide “ITS2b” which is complementary to sequences within ITS2
(sequences shown Table 1).
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5S RNA is selectively decreased in cells haploinsufficient for RPL5
To determine if we could identify unique pre-rRNA processing
characteristics associated with any of the large subunit protein genes studied
here, we analyzed the membrane above (Fig. 7) using additional probes. The
most striking difference between the pre-rRNA processing patterns for the
affected genes is the decrease in 5S rRNA observed in the cells derived from a
patient with mutated RPL5 (Fig. 8B). The decrease is selective for 5S RNA as
there is little change in 5.8S RNA in the RPL5 sample compared to the others
(Fig. 8C). Thus, it may be possible to further refine the diagnostic power of prerRNA processing to identify signatures associated with specific ribosomal protein
gene mutations.
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Fig 8: Northern Blots of DBA patient samples reveal a unique processing
signature in a patient where RPL5 is mutated.
Total RNA from stimulated blood mononuclear cells was transferred to zeta probe
membrane and hybridized with probes listed in Table 1. Names of probes used
in the labeling of the Northern blots are shown at the top of each panel. The
gene mutated in each sample is listed above each lane, with the healthy control
samples listed as Wt.
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The 5S RNA subcomplex as a possible mediator of ribosome stress signaling
The decrease in 5S rRNA in samples from patient’s haploinsufficient for
RPL5 has a number of implications for DBA pathophysiology. The 5S RNA is
unique among the four rRNA species found in eukaryotic cytoplasmic ribosomes.
It is the only rRNA transcribed independently by RNA polymerase III, as opposed
to the other three rRNAs transcribed together by RNA polymerase I (Allison et al.,
1995; Ciganda and Williams, 2011; Zhang et al., 2007). This unusual
organization lends itself to the potential adaptation of 5S RNA and its associated
proteins, RPL5 and RPL11, as a novel signaling subcomplex of the ribosome. In
fact, many studies have suggested that ribosome stress is mediated through the
interactions of RPL5 and RPL11 with MDM2, which results in stabilization and
activation of p53 (Honda et al., 1997; Kubbutat et al., 1997). Additional work has
implied that 5S rRNA is involved in this process by forming a stable subcomplex
with RPL5 and RPL11 and that it is the subcomplex that actually interacts with
MDM2 in vivo as shown by the synergistic inhibition of MDM2 activity (Allison et
al., 1995; Fumagalli et al., 2009; Horn and Vousden, 2008; Lipton and Ellis,
2010).
While the view that this ternary complex may be free to interact with
MDM2 when large subunit assembly is disrupted by haploinsufficiency for any
large subunit ribosomal protein other than RPL5 and RPL11 themselves, it is less
clear why this complex may be freed to interact with MDM2 when small subunit
assembly is affected. Therefore, we were interested in whether there may be an
increase in free 5S RNA in samples where 40S subunit assembly is disrupted by
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reduced expression of RPS19. To address this question, we turned to human
TF-1 cells where RPS19 expression can be regulated by an inducible shRNA to
RPS19 mRNA (Flygare et al., 2007). Fig. 9 shows polysome profiles from cells
depleted of RPS19 and scrambled controls. Cells depleted of RPS19 show a
decrease in free 40S subunits, an increase in free 60S subunits, and a shift from
larger to smaller polysomes. This is the expected outcome for a small subunit
biogenesis defect. When 40S subunits are limiting, both 40S and 80S species
are decreased whereas free 60S subunits increase since 40S pre-initiation
complexes are no longer available. To monitor the fate of 5S rRNA under these
conditions, RNA was precipitated from the polysome fractions of these samples
and then used for Northern blotting. Interestingly, the fraction of 5S rRNA in the
free pool found at the top of the gradient is increased approximately 3-fold from
~5 to 15% in cells depleted of RPS19 relative to control samples. While not
conclusive, these data suggest that increases in the 5S RNA subcomplex may
occur in cells depleted of RPS19, and in doing so be available for signaling
ribosome stress to regulators of p53.
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Figure 9: Polysome profiles of TF-1 samples depleted of RPS19 show an
increase in the free pool of 5S rRNA.
TF-1 B and TF-1 SCR cells were treated with doxycycline for seven days to
stimulate expression of shRNAs targeting RPS19 (TF1-B) shown in (B) or a
scrambled control sequence (TF1-SCR) shown in (A). The resulting extracts
were prepared in the presence of cycloheximide and separated by
ultracentrifugation on sucrose gradients. Each panel shows representative
absorbance tracings at 254nm and Northern blots of gradient fractions probed
with oligonucleotides complementary to either 5S or 5.8S rRNA are shown below.
Panel C shows the fraction of 5S rRNA found at the top of each gradient relative
to the total amount of 5S rRNA across the gradients. Values for the amount of
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5S rRNA in each fraction were obtained by phosphorimage analysis using
Imagequant (GE). Free 5S was determined by adding the band intensities of
lanes delineated “Free 5S” above the Northern blots over the sum of the 5S
rRNA signals. Free 5.8S rRNA was quantified in a similar manner (data not
shown), but with equivalent results in both control and knockdown samples. Error
bars represent S.D. with n= 4 and a *p<0.05 value as determined by an unpaired
student’s t-test.
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The amount of free 5S RNA in cells depleted of Rps19 was also
investigated in a different model system of mouse embryonic stem cell lines
(mES) where a single copy of the Rps19 gene is interrupted by insertion of a
genetrap retroviral construct between exons 3 and 4. This leads to a truncated
mRNA transcript as outlined in the materials and methods chapter. The genetrapped embryonic stem cells were purchased from the Mutant Mouse Regional
Resource Centers, MMRRC. The system was chosen by one of our collaborators
to investigate the effects of heterozygosity for Rps19 on different aspects of
mouse development in in vitro differentiation assays (see appendix). Extracts
from the Rps19 gene trap and parental controls labeled YHC and E14,
respectively were treated as described above for TF-1 cultures and analyzed in
the same manner. The results showed the free pool of 5S rRNA increased from
18% to 25% in the Rps19 gene trap samples relative to control (Fig. 10). Though
not as striking a result as those found in the TF-1 model, ribosome defects in
mouse models are often less severe then those in human cell lines (Flygare et
al., 2007; Flygare et al., 2005; Gazda et al., 2004; Jaako et al., 2011). In
contrast, mES models that recapitulate Rpl5 heterozygosity displayed essentially
no change in the free pool of 5SrRNA (Fig. 11).
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Fig 10: Free 5S rRNA is increased in mouse embryonic stem cells
heterozygous for Rps19
RNA was precipitated from polysome fractions of YHC (Rps19 mutant) and their
corresponding parental control (E14) mES lines. Northern blots of the RNA
samples are shown in the top panels and the band intensity quantified in the
lower panel’s table using Imagequant (GE). Percentages of rRNA samples in
each category were calculated by adding the band intensity of each of the lanes
in the same category and dividing by the total band intensity.
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Fig 11: Free 5S rRNA is unchanged in mouse embryonic stem cells
heterozygous for Rpl5
RNA was precipitated from polysome fractions of D050 (Rpl5 mutant) mES and
their corresponding parental control (YHC). Northern blots of the RNA samples
are shown in the top panels with the quantification performed using Imagequant
software (GE Healthcare) below. The amount of 5S rRNA in the first six lanes
were classified as the free pool, whereas that in lanes from 60S through the
polysome fractions were considered 60S associated as localized by the
cosedimintation of 5.8S rRNA. The Table shows the relative amount of 5S rRNA
found in each fraction.
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The 5S rRNA released with abortive assembly in our mES model of small
subunit protein mutations is presumably free to interact with MDM2 (in
association with Rpl5 and Rpl11) to prevent MDM2 mediated degradation of p53.
In the case of the Rpl5 mES model, there is no corresponding increase in 5S
rRNA in the free pool. Nevertheless, there appears to be an increase in p53
protein expression in each of the gene trap cell lines (Fig. 12). In the S17
derived Rps19 mutant cell lines, this increase in p53 protein expression is
evident in the undifferentiated mES cells (Fig. 12A). After stimulation to form
embryoid bodies, as described in the supplemental section for use as a model of
primitive hematopoiesis (Fig S4). The YHC Rps19 cell model, as well as the Rpl5
model, D050, shows an increase in p53 protein expression. These results are
consistent with a model where p53 activation in cells haploinsufficient for Rpl5
occurs through a mechanism distinct from that of other ribosomal protein genes,
excluding Rpl11.
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Fig 12: Cells heterozygous for either Rps19 or Rpl5 show an increase in
p53 expression relative to controls.
(A) Duplicate samples of control (ORF-17) or Rps19 gene trap (EMT-S17) mES
cells whole cell lysates were used for SDS-PAGE. Anti-sera for p53, β-Actin, and
Rps19 were used for the western blots. (B) Rpl5 or Rps19 gene trap mES cells
were differentiated into embryoid bodies and then harvested and whole cell
lysates used for western blotting using anti-sera for p53, β-Actin, and Rps19. (C)
Band intensities of western blots were quantified using ImageJ. Data in the bar
graph represent the means of multiple exposures of multiple experimental
replicates, error bars = S.D., *p<0.05 as determined by unpaired Student’s t-test.
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Discussion
The case reported here illustrates some of the complexities associated
with making a definitive diagnosis of an inherited bone marrow failure syndrome.
The child presented with anemia and neutropenia with congenital anomalies
characteristic of both Diamond Blackfan anemia and Fanconi anemia. The
neutropenia could also suggest Shwachman Diamond syndrome (Shimamura
and Alter, 2010). Fanconi anemia was ruled out, as the child’s cells did not
appear to be unusually sensitive to DNA crosslinking agents as would be
expected for this disease (Shimamura and Alter, 2010). This sensitivity stems
from the fact that the underlying molecular defect in FA resides in DNA repair at
sites of double strand breaks (Soulier, 2011). Sequencing the SBDS gene and
the 10 known pathogenic ribosomal protein genes associated with DBA in this
child also revealed no obvious mutations, further complicating the potential of an
accurate diagnosis.
The finding that this child had a 2.3 megabase deletion including the gene
encoding ribosomal protein RPL31 suggested that she might indeed have DBA
resulting from ribosomal protein haploinsufficiency. If confirmed, these studies
would identify RPL31 as a new DBA gene. Demonstration of a ribosome
biogenesis defect can help add to a DBA diagnosis, but analyses such as
Northern blotting and polysome profiling are restricted to a few research
laboratories and are unlikely to be adopted in clinical laboratories. This is, in
part, due to the complicated equipment used to generate polysome profiles and
the personnel hazards associated with the radiation used in common Northern
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blotting techniques. Having a facile assay that does not involve radioisotopes
would greatly improve the prospects of monitoring for defects in ribosome
synthesis as a diagnostic tool for DBA.
The data reported here clearly demonstrate that the proband in the index
case has a pre-RNA processing pattern indicative of a defect in the maturation of
the 60S subunit as would be expected for haploinsufficiency for a large subunit
ribosomal protein. These results strongly support a diagnosis of DBA for this
patient and also identify RPL31 as a new DBA gene (Campagnoli et al., 2008;
Choesmel et al., 2007; Farrar et al., 2008; Gazda et al., 2008; Jaako et al., 2011;
Robledo et al., 2008; Rouquette et al., 2005).
The studies reported here also show that patients with mutations in genes
encoding large subunit ribosomal proteins have a common pre-rRNA processing
defect visualized at the level of an ethidium bromide-stained gel. We strongly
feel that this observation could be readily adapted to a routine assay for patients
with defects in 60S subunit assembly, which could aide in DBA diagnosis and
gene discovery efforts. This assay could be performed in a gel format as
reported here, or could be readily adapted to testing in a Bioanalyzer, commonly
used to test RNA integrity prior to quantitative PCR techniques.
An additional outcome of our investigation of pre-rRNA processing
patterns in DBA patients with mutations in large subunit ribosomal protein genes
was the demonstration that mature 5S rRNA is dramatically and selectively
decreased in patients haploinsufficient for RPL5. RPL5 has been known for
many years to bind directly to 5S rRNA (Allison et al., 1995; Thomas and Kutay,
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2003). Work in recent years has shown that RPL11 and two additional ribosome
associated proteins are required for the incorporation of the 5S subcomplex into
assembling 60S subunits (Ciganda and Williams, 2011; Dai et al.; Grandi et al.,
2002; Hadjiolova et al., 1993; Horn and Vousden, 2008; Kubbutat et al., 1997;
Lohrum et al., 2000; Lohrum et al., 2003; Zhang et al., 2007).
In addition to its role as a vital component of the 60S subunit, increasing
data suggest that this subcomplex also plays a critical role in ribosomal stress
signaling. The complex of 5S rRNA together with RPL5 and RPL11 has been
shown to bind to the ubiquitin ligase MDM2 and inhibit its activity toward p53
resulting in an increase in the amount and activity of p53 (Dai et al., 2007a; Dai
and Lu, 2004; Dai et al., 2007b; Dai et al., 2006; Dai et al.; Dai et al., 2004;
Montanaro et al., 2007; Sun et al., 2007).

This ribosome stress signaling

pathway has been reported in several studies to play an important role in the proapoptotic phenotype of erythroid precursors in DBA (Badhai et al., 2009; Dai and
Lu, 2008; Danilova et al., 2008; Horos et al., 2012; Jaako et al., 2011; Kuramitsu
et al., 2008; Miyake et al., 2008; Ofir-Rosenfeld et al., 2008; Uechi et al., 2008).
Consistent with this view, our data indicate that the level of free 5S rRNA
(presumably in complex with RPL5 and RPL11) increases even in cells where
small subunit ribosomal proteins are depleted in both a human cell line and in
mouse embryonic stem cell models of DBA. Thus, the 5S rRNA subcomplex may
play a critical role in ribosome stress signaling and thereby an important role in
the pathophysiology of most cases of DBA.
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A critical role of the 5S rRNA subcomplex in ribosome stress signaling in
DBA patients seems at odds with the finding that both RPL5 and RPL11 are DBA
genes. Our observation that 5S rRNA is dramatically decreased in patient
samples from a patient haploinsufficient for RPL5 strongly suggests that the 5S
rRNA subcomplex would be limiting for 60S subunit formation leaving little
available for stress signaling. This apparent paradox could be reconciled if there
were an alternative pathway used to signal ribosome stress in such cells. Such a
pathway could dominate in cells where the 5S rRNA subcomplex was unavailable
such as in patient’s haploinsufficient for RPL5 or RPL11. Interestingly, this
alternative pathway may have characteristics distinct from the 5S rRNA
subcomplex in ribosome stress signaling as DBA patients with mutations in RPL5
and RPL11 tend to have more severe forms of the disease with a greater
spectrum of congenital anomalies including cleft lips and palates (Gazda et al.,
2008). The existence of this alternative pathway in patients with RPL5 mutations
is supported by the observation that p53 levels increase in the cells without an
increase in the pool of free 5S rRNA (Fig. 11-12).
As the patient reported here is the first to have a mutation in RPL31 it is
too soon to tell if all of her clinical characteristics stem from the loss of RPL31. It
is possible that some of her clinical features may be caused by loss of other
genes in the deleted region. As RPL31 will likely now be included for sequence
analysis in DBA patients lacking mutations in other known genes, it is possible
that other patients will be identified that only have mutations in this gene. The
clinical features of such patients will help resolve this issue.
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Conclusions and Future Directions
This work identifies RPL31 as a new potential DBA gene and adds to the
growing list of ribosomal protein genes known to be mutated in this puzzling bone
marrow failure. These studies represent the first description of a possible
diagnostic assay for DBA patients with mutations in large subunit ribosomal
protein genes based on the visualization of increased 32S pre-rRNA with UV light
in standard RNA gels. The straight-forward nature of this assay could lend itself
to high throughput methods more amenable to a clinical diagnostic laboratory
such as bioanalyzers routinely used for assaying RNA quality for reverse
transcription PCR.
After identification of this patient as a non-classical DBA patient, the child
and her family, can obtain information, support, and guidance associated with the
already existing infrastructure of the North American DBA Registry. Though the
patient whose samples containing a deletion of RPL31 made this research
possible died during the course of this study, her family will remain a part of the
DBA family. May this research be a celebration of her life!
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CHAPTER IV
MITOCHONDRIAL DYSFUNCTION IN A HUMAN CELL LINE MODEL OF
SHWACHMAN DIAMOND SYNDROME

Introduction
Shwachman Diamond syndrome (SDS; OMIM 260400) is one of a class of
inherited bone marrow failure syndromes (IBMFS). Its clinical presentation
typically includes exocrine pancreatic insufficiency, cartilage disorders, and
neutropenia, though deficits in multiple blood lineages have been seen in
patients (Burwick et al., 2011). Patients with SDS have a greatly increased risk
for myelodisplastic syndromes (MDS) and acute myelogenous leukemia (AML).
Some studies estimate up to 40 percent of SDS patients will be affected MDS/
AML by age 30 (Donadieu et al., 2005; Dror and Freedman, 2002; Shimamura
and Alter, 2010; Smith et al., 1996; Tamary et al., 2010). Over 90% of SDS
patients have pathogenic mutations in the gene SBDS (Shwachman Bodian
Diamond Syndrome) (Boocock et al., 2003). The majority of mutations are
located in exon two with many resulting from gene conversion with the adjacent
pseudogene (Burroughs et al., 2009). The diverse biological systems affected by
mutations in SBDS suggest that SBDS may be a multifunctional protein. SBDS
is reported to have many functions including ribosome biogenesis (Austin et al.,
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2005; Finch et al., 2011; Ganapathi et al., 2007; Menne et al., 2007; Moore et al.,
2010; Orelio et al., 2011; Vitiello et al., 2010; Wessels et al., 2006; Wong et al.,
2011), maintenance of bone marrow stromal environment (Leung et al., 2011),
chemotaxis, mitotic spindle stability (Austin!et!al.,!2008;!Orelio!and!Kuijpers,!2009;!
Orelio!et!al.,!2009) and regulating apoptosis pathways (Ambekar et al., 2010;
Rujkijyanont et al., 2008; Watanabe et al., 2009).
Much of our current knowledge regarding SBDS function in ribosome
biogenesis was obtained using yeast models lacking SDO1, the yeast ortholog of
SBDS. One possible explanation for the multiple functions associated with the
loss of SBDS in human cells is that some of these properties are a consequence
of downstream effects of the loss of members of the SBDS protein family on
translation output. To address this issue, Dr. Joseph B Moore IV in our laboratory
analyzed the effect of loss of SDO1 on translation in yeast. To this end, cells
were pulse labeled for 30 minutes with [35S]-Met and proteins resolved by twodimensional gel electrophoresis. Fig. 13 shows the results of this analysis. One
of the proteins shown to be substantially increased in ΔSDO1 cells relative to
controls was identified as Por1, the yeast ortholog of VDAC1, a voltage
dependent anion channel of the mitochondrial outer membrane (McDonald et al.,
2009). This observation led us to the finding that yeast cells lacking Sdo1 were
incapable of growing on non-fermentable carbon sources indicating that they had
defective mitochondrial function. The studies described in this chapter are
focused on mitochondrial function in a human erythroleukemia cell line depleted
of SBDS. The first portion of this chapter will discuss the development and
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characteristics of a human cell line depleted of the SBDS protein, while the
remaining studies will focus on testing the hypothesis that mitochondrial function
may be disrupted in cells depleted of SBDS.
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Fig 13: Por1 expression is increased in ΔSDO1 yeast strain
Wild-type (left panels) and ΔSDO1 (right panels) strains were incubated for 30
minutes with [35S]-Methionine. Total protein extracts were resolved by 2D gel
electrophoresis. The pH gradient for IEF was 3-10. The second dimension was
resolved via a 4-12% polyacrylamide gel. Molecular masses for size standards
are shown to the left. Regions enclosed by the boxes are expanded above each
gel. The spot labeled Por1 was excised and identified via MALDI-TOF mass
spectrometry.
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Results

Targeting SBDS gene expression in the human erythroleukemia TF-1 cell line
Our goal was to create a tissue culture model for Shwachman Diamond
syndrome by using shRNA technology to reduce expression of SBDS in a human
cell line. This approach was necessary given the limited availability of patient
samples for this rare bone marrow failure syndrome. SBDS is a multifactorial
bone marrow failure that has been shown to affect numerous blood cell lineages,
so the TF-1 erythroleukemic cell line was chosen for its ability to differentiate
along various myeloid lineages (Dror and Freedman, 1999; Leung et al., 2011;
Miyake et al., 2005; Rawls et al., 2007; Sen et al., 2011; Wong et al., 2011).
Steady-state levels of SBDS were monitored in cell lines transduced with
lentiviral vectors expressing shRNAs to SBDS or scrambled controls. To this
end, whole cell extracts were prepared, proteins fractioned by SDS-PAGE,
transferred to nitrocellulose filters and immunoblotted with anti-sera raised
against SBDS, or β-actin as a loading control. Fig. 14A shows that relative to
scrambled controls the steady-state amount of SBDS was reduced to near
undetectable levels. Reduced SBDS expression was also observed at the
mRNA level as determined by qRT-PCR (Fig. 14B). SDS is an autosomal
recessive disease with most patients expressing very low levels of SBDS,
typically from hypomorphic alleles. Consequently, only clones expressing SBDS
at levels below 30% of wild-type were used for subsequent studies.

88

Fig 14: Steady-state amounts of SBDS protein and mRNA in TF-1 clones.
(B) Immunoblot of whole cell lysates of TF-1 cells transduced with lentiviruses
expressing shRNAs against SBDS mRNA or scrambled controls. Membranes
were blotted with anti-sera raised to SBDS or β-actin. (A) qRT-PCR of SBDS
mRNA from total RNA isolated from lentiviral transduced TF-1 cells. Each bar in
the graph represents a different clone created during the selection process with
the numbers corresponding to the sequence of the SBDS plasmid used to
transduce the TF-1 cells.
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Reduced SBDS expression slows growth rate and affects 60S subunit maturation
TF-1 cells depleted of SBDS protein have a slower growth rate when
compared to the scrambled control samples (Fig 15) in congruence with previous
cell models of SDS (Menne et al., 2007; Moore et al., 2010). The reduced
growth rates of human cell line models of SDS have been correlated with
adverse effects on the maturation of 60S ribosomal subunits and translation.
This should come as no surprise with loss of a protein that is integral in 60S
subunit maturation. The status of the translational machinery in our model
system was investigated by a technique called polysome profiling. Extracts
suitable for polysome profiling were prepared by harvesting cells in the presence
of cycloheximide, which inhibits the elongation phase of translation and traps
ribosomes on mRNAs. Extracts prepared in the presence of cycloheximide were
then subjected to sucrose gradient centrifugation. Gradients were fractionated
and absorbance at 254 nm was monitored. A representative absorbance tracing
is shown in (Fig 16) where cells depleted of SBDS exhibit a modest decrease in
free 60S subunits and 80S subunits. More importantly, the decreased
absorbance in the polysome region indicates a defect in the formation of mature
ribosomes that are actively participating in translation.
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Fig 15: Cells depleted of SBDS have a reduced growth rate relative to
scrambled controls.
TF-1 cells treated with lentiviral vectors targeting SBDS expression (dashed line)
or a scrambled control (solid line), were counted using trypan blue exclusion for
cell viability. (n=3, error bars represent S.D.).
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Fig. 16: Polysome profiles from TF-1 cells depleted of SBDS and a
scrambled control.
The above image is a representative absorbance tracing at 254 nm of TF-1 cells
fractionated by sucrose gradient centrifugation. Black: scrambled control; Red:
shRNA to SBDS #2. Cells were harvested in the presence of cycloheximide as
previously described (16). The absorbance tracing was captured using an ISCOUV/Vis detector UA-6 and ISCO optical unit type II. Samples were normalized
relative to the trough following the 40S subunit peak. This result was
recapitulated in four independent experiments.
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Previous results have demonstrated a role for SBDS in the release of eIF6
from 60S subunits. The eIF6 protein associates with pre-60S subunits in the
nucleolus and plays an important role in transporting pre-60S particles from the
nucleus to the cytoplasm. The eIF6 also has anti-subunit association activity
which prevents 60S subunits from joining with 40S subunits before they are fully
matured. The failure to release eIF6 from 60S subunits in the absence of SBDS
prevents 60S subunits from prematurely binding to 40S subunit during formation
of the 80S initiation complex (McDonald et al., 2009; Nihrane et al., 2009;
Rujkijyanont et al., 2008). To monitor the relative distribution of eIF-6 between
free and 60S subunit-bound pools, gradient fractions were immunoblotted for the
presence of eIF6. Antibodies against RPS19 and RPL5 were used as controls to
identify peaks for the small and large subunit, respectively (Fig. 17, top panel).
These data revealed an approximately 20% increase in eIF6 co-sedimenting with
60S subunits in cells depleted of SBDS. This increase in association with the 60S
subunit was shown to be reproducible and statistically significant (n=4, p = 0.001
as determined by an unpaired Student’s t-test).

!

93

Fig. 17: Distribution of eIF6 in sucrose gradients derived from TF-1 cells
depleted of SBDS and scrambled controls.
Top panel: representative immunoblots of proteins precipitated from sucrose
gradient fractions of TF-1 cells transduced with the Sigma Aldrich SBDS shRNA
#2 or scrambled (Scr) lentiviral constructs. The fractions on the far left
correspond to the top of a gradient. Fractions were precipitated with 10%
trichloroacetic acid, washed, resuspended in SDS sample buffer, and 1/10 of
each fraction was loaded on a gel for subsequent immunoblotting. Anti-sera to
ribosomal proteins RPS19 and RPL5 were used to identify fractions containing
40S and 60S subunits, respectively. 60S subunits and 80S monosomes were
not completely resolved in this experiment. The signal intensity in immunoblots
were quantified using ImageJ software. Data in the bottom panel are plotted as a
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ratio of eIF6 co-sedimenting with 60S subunits over eIF6 present in remaining
fractions at the top of the gradient. The percentage of eIF6 co-sedimenting with
the 60S subunit fraction was increased by about 20% relative to controls in cells
depleted of SBDS (1.26 in the SBDS #2 samples and 1.04 in the control
samples, n=4, column= mean, error bars = SEM, **p≤0.01 as determined by an
unpaired Student’s t-test).
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SDS model exhibits cell cycle delay and maturation defects
Previous work with cellular models of SBDS has shown a delay in cell
cycle progression (Ambekar et al., 2010; Ball et al., 2009; Wong et al., 2011). To
further validate our model, cell cycle progression was analyzed by flow cytometry
after permeabilizing cells and treating with RNAse and propidium iodide. A small
but statistically significant delay in cell cycle progression was observed in cells
depleted of SBDS. This delay is observed as an average increase of cells in G0/
G1 of approximately 6%, with a corresponding decrease in the percentage of
cells in S phase (Fig. 18).
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Figure 18: Analysis of cell cycle progression in cells depleted of SBDS and
scrambled controls.
Cells depleted of SBDS and scrambled controls were stained with propidium
iodide and cell cycle phase was monitored by flow cytometry in the FL3H-PI
channel.
Top panel: The average of six independent experiments with the standard
deviation used for error bars. Data were compared by ANOVA, the difference
between cells present in G0/G1 relative to S was calculated using an appropriate
post-hoc test as 8%, with **p < 0. 01.
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Bottom panel: representative histograms with the shaded regions depicting the
most likely mathematical model as determined by the Dean/Jett/Fox method
using FlowJo software. The first peak, containing 2N DNA content represents
cells in the G0/G1 phase. The peak at the far right represents cells that have 4N
DNA content and are in the G2/M phase of the cell cycle. The intermediate cells
are in the synthesis phase and have varying DNA content. The black outline
shows the histogram of raw data generated with the mathematical algorithm of
the Dean/Jett/Fox method calculating the most likely peak representations of the
three cell populations.
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The depletion of SBDS in TF-1 cells also gave us an opportunity to
determine the effect of this depletion on the ability of these cells to differentiate
along the erythroid and granulocyte lineages. TF-1 cells can be induced to
differentiate along the myeloid or erythroid lineages in response to the cytokines
GM-CSF (granulocyte and macrophage colony stimulating factor) and EPO
(erythropoietin), respectively. Differentiation is evaluated by colony formation in
methylcellulose media. A cluster is considered a “colony” if it contains 40 or more
cells and plating density is such that that many cells in a cluster have originated
from a single progenitor (Miyake et al., 2005). This is analogous to the bone
marrow derived hematopoietic stem cells giving rise to committed progenitors
that form colony forming units (CFUs) and as they commit to a particular lineage,
in this case burst forming units of the erythroid, or granulocyte lineage, BFU-E
and GM-CFU respectively. These cells then continue to grow as clumps derived
from the same progenitor that divide to form a clone or further differentiate
(Metcalf, 2007). The viscous medium provides a matrix for the mutli-potent cells
to differentiate toward a particular cell lineage based on which cytokines are used
to stimulate them. This is a common experimental model used to investigate
IBMFS that have a delay or block in maturation of specific blood lineages. Fig.
19 shows a decrease in the ability of SBDS-depleted TF-1 cells to differentiate
down both erythroid and granulocyte lineages consistent with defects seen in
SDS patient samples performed by Dr. Sharon Singh in the laboratory of Dr.
Johnson Liu (Nihrane et al., 2009; Orelio et al., 2009; Rawls et al., 2007; Sen et
al., 2011; Yamaguchi et al., 2007).
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Figure 19: Analysis of erythroid and granulocyte differentiation of TF-1
cells depleted of SBDS or scrambled controls
TF- 1 cells were differentiated into either myeloid or erythroid colonies using GMCSF or EPO in methylcellulose media. The #2-12 SBDS knockdown clone had
decreased myeloid (A) and erythroid (B) colony formation when compared with
the scrambled #4 control. Markedly smaller colonies were also seen in the #2-12
clone (C) and (D) . * p=0.0040 ***p=0.0004.
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Changes in oxygen consumption in SDS model
Previous results in our laboratory showing that yeast Δsdo1 strains were
unable to grow on non-fermentable carbon sources sparked our desire to
address aspects of mitochondrial function in TF-1 cells depleted of SBDS. In
yeast, it was possible to assess mitochondrial function by monitoring growth on
non-fermentable carbon sources. Similar experiments cannot be performed in
human cells. Consequently, we used a number of alternative strategies to
assess mitochondrial function in TF-1 cells depleted of SBDS.
One of these strategies was to monitor oxygen consumption. Oxygen
consumption was monitored using a Gilson type oxygraph with a Clark-type
electrode (Campian et al., 2007; Gao et al., 2010). These experiments were
performed with the equipment and guidance of Dr. John Eaton’s laboratory. Fig.
19 shows that cells depleted of SBDS consumed less oxygen compared to
scrambled controls. Both basal and maximal rates of oxygen consumption are
decreased, as evidenced by a difference in slopes between the two tracings in
Fig. 20A both before and after the addition of the uncoupling agent CCCP. A
greater effect on basal respiration is evident when the ratios of basal to maximal
respiration are taken into consideration in the graphs depicting the averages of
three independent experiments (Fig 20B).
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Fig 20: Oxygen consumption by TF-1 cells depleted of SBDS compared
with scrambled controls.
A. Representative oxygen concentration tracings with time before and after
addition of 10mM CCCP, B. Data from panel A were converted to µmol of
oxygen consumed per million cells per minute and plotted as ratio of basal over
maximum oxygen consumption rate. Averages of three independent experiments
are shown with error bars showing S.E.M. (*p<0.05 as determined by an
unpaired Student’s t-test)
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Changes in mitochondrial membrane potential and mitochondrial protein
expression with SBDS knockdown
Oxygen consumption is linked to ATP synthesis in mitochondria through
the chemiosmotic membrane potential created by protons pumped from the
mitochondrial matrix to the inner membrane space via electron transport. Given
the decrease in oxygen consumption in TF-1 cells depleted of SBDS, we were
interested in whether this finding could be linked to a decrease in mitochondrial
membrane potential (Wurm et al., 2011). The Mitoprobe JC-1 assay was used to
examine mitochondrial membrane potential in TF-1 cells depleted of SBDS and
scrambled controls. Cells treated with the JC-1 dye were analyzed by flow
cytometry. The JC-1 dye undergoes a membrane potential dependent shift in
emission spectrum from green (529 nm) to red (590 nm) as it enters and
accumulates within the mitochondrial matrix (Chaoui et al., 2006; Chazotte,
2011; Cossarizza and Salvioli, 2001; Garner and Thomas, 1999; Guthrie and
Welch, 2008; Keil et al., 2011; Legrand et al., 2001; Lugli et al., 2007; Reers et
al., 1995; Salvioli et al., 1997; Simeonova et al., 2004; Smiley et al., 1991).
Mitochondria with normal membrane potential should be able to retain a
significant quantity of the dye and stain intensely in the red emission spectrum
and fluorescence in the green emission spectrum validates the use of
appropriate concentration of the compound were used in staining.
After gating to remove debris and dead cells in a separate plot of side
scatter (SSC) and forward scatter (FSC) such that these signals were not
included in the analysis a minimum of 40,000 events were counted in each
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experimental replicate. Data were plotted with red fluorescence on the Y axis
(captured with the FL2H channel) and green on the X axis (captured with the
FL1H channel). Quadrants were centered such that greater than 97% of the
unstained control sample was found in the lower left quadrant. Positive controls
were created in each replicate by pre-treating cells with CCCP, an electron
transport chain uncoupler which should cause the mitochondrial membrane
potential to greatly decrease. These samples were found predominately in the
lower right quadrant. Thus, the majority of cells will be located in one of two
quadrants. Cells highly fluorescing in both the green and red spectrum, as would
be expected of cells with normal mitochondrial membrane potential, are found in
the upper right quadrant and cells with lower membrane potential will be in the
lower right quadrant because they have more intense fluorescence emissions in
the green rather than the red emission spectrums corresponding to cells with a
proportionally higher amount of JC-1 dye in the cytoplasm rather than retained
inside the mitochondria.
The bulk of cells in the control population treated with JC-1 are found in
the upper right quadrant with relatively high red and green staining and so
represents normal mitochondrial membrane potential for TF-1 cells (Fig. 21A).
Cells depleted of SBDS show a significantly different staining pattern with a
significantly decreased level of red fluorescence in the majority of cells (Fig.
21B).

This shift is consistent with a decrease in mitochondrial membrane

potential in cells depleted of SBDS. Three independent experiments were
analyzed to determine relative fractions of normal mitochondria (based on their
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location in the upper right quadrant) in cell depleted of SBDS relative to controls.
The results from these analyses are shown in Fig. 21C. On average 72.8 +/- 3 %
of scrambled samples were found in the upper right quadrant representing TF-1
cells classified as having normal mitochondrial membrane potential. In contrast,
57.5% +/- 2% of SBDS knockdown cells were found in this quadrant with a
corresponding shift to the lower right quadrant representing cells with decreased
mitochondrial membrane potential (Fig. 21, n=12-14 and range = S.E.M., p value
< 0.001 as determined by Student’s two-tailed t-test). A Fisher’s exact test to
assess whether the use of Student’s t-test was appropriate for these analyses
found the variance between the two means to lack significance, making the
Student’s t-test an appropriate choice for statistical analysis. When individual
clones were compared using one-way repeated measures ANOVA, the means
between different clones were also found to be statistically significant and a
Dunnett’s multiple comparison post-hoc test with p values all less than 0.01.
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Fig 21: Analysis of mitochondrial membrane potential in cells depleted of
SBDS and scrambled controls
Flow cytometric analysis of cells treated with JC-1, a cationic dye that
accumulates in mitochondria in a membrane potential-dependent manner. The
JC-1 dye undergoes a fluorescence emission shift from green (529 nm) to red
(590 nm) upon entry into mitochondria. Representative histograms are shown
where FL2-H: JC-1 red fluorescence is plotted on the y-axis and FL1-H: JC-1
green fluorescence on the x-axis. (A) scrambled control TF-1 cells treated with
JC-1 (B) TF-1 cells depleted of SBDS treated with JC-1. Samples were analyzed
using FlowJo software as outlined in the Materials and Methods section. Data
are plotted as a contour map with cell densities denoted by color and peaks
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evident by decreased separation between contour lines. (C) Replicate data from
three independent experiments are plotted as the percentage of TF-1 cells
containing normal mitochondria as delineated by the upper right quadrant. Error
bars represent S.E.M. (n=3, ***p<0.001 as determined by an unpaired Student’s
t-test)
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The data presented thus far indicate that cells depleted of SBDS have
reduced oxygen consumption and reduced mitochondrial membrane potential.
This decrease in mitochondrial function could arise from decreased mitochondrial
mass within the cell or be the consequence organelles with reduced function. To
assess levels of total mitochondria between cells depleted of SBDS and
scrambled controls, we examined the expression of a number of mitochondrial
proteins found in various locations within the organelle (see Table 2 for proteins
examined). Unfortunately, no consistent patterns of expression were found in
this analysis. Tom20 and Tom40 represent components of the mitochondrial
import machinery and might be classified as more or less constitutive
components of the organelle. Despite being part of the same complex, the
amount of Tom40 increased in cells depleted of SBDS relative to controls
whereas the level of Tom20 went down (Fig. 22). Similarly, SOD2 and IDH2, two
enzymes involved in reducing oxidative stress, also revealed discordant
responses with SOD2 showing decreased expression with IDH2 increasing (see
Fig. 21 for representative data). Interestingly, two enzymes involved in energy
metabolism, pyruvate dehydrogenase (PDH) and isocitrate dehydrogenase, both
decreased in expression. The same is true for cytochrome c which plays an
important role in energy metabolism as a component of the electron transport
chain. Finally, the expression of VDAC1 went up in cells depleted of SBDS
consistent with the results in yeast, where Por1, the yeast ortholog of VDAC1,
was increased in cells depleted of Sdo1 (Fig 23).
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Protein

Location

Tom20

OMM

Tom 40

OMM

VDAC1

OMM

SOD 2

MM

PDH

MM

IDH2

MM

IDH3α

MM

Cytochrome C

IM

Function

Expression
change

Portion of import channel that
Forms the receptor site with Tom22 of
the major mitochondrial protein
importer. (TOMM)
Forms the channel portion of the
TOMM import complex
Voltage!dependent!ion!channel!
Mitochondrial specific neutralizer of
super oxide from electron transport
chain
Decarboxylates pyruvate to form
acetyl-CoA, a TCA cycle substrate.
NADP(+) dependent, catalyzes the
formation of α-ketoglutarate from
isocitrate
TCA cycle enzyme
NAD(+) dependent, catalyzes the
formation of α-ketoglutarate from
isocitrate
Loosely associates with the IMM in the
IM. Serves was a carrier of electrons
from Complex III to Complex IV of the
electron transport chain

!
"
"
!
!
"

!

!

Table 2: Mitochondrial proteins analyzed using immunoblotting
Mitochondrial proteins, their locations, functions, and relative changes in
expression between cells depleted of SBDS and scrambled controls are shown.
Changes in expression were determined by quantification with ImageJ software
of band density normalized to a tubulin loading control using several different
exposures for each blot and at least three replicate sample preparations in each
cell type. (OMM=outer mitochondrial membrane, MM= mitochondrial matrix, IM=
inner membrane of mitochondria)
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Average Expression Relative to Tubulin
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SBDS

Fig 22: Steady state levels of representative mitochondrial proteins in cells
depleted of SBDS relative to Scr controls.
Upper Panel: Immunoblots of whole cell lysates from TF-1 cells transduced with
lentiviral vectors targeting SBDS gene expression or scrambled controls.
(Black lines indicate a space in the membrane for protein size standard.)
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Lower Panel: Quantification of band intensity using ImageJ software. Each bar
represents the average of multiple band intensities over multiple experiments and
exposures relative to a tubulin loading control. Error bars = S.E.M.
(Cyt. C - Cytochrome C, SOD2 - superoxide dismutase 2, F.H.- Fumarate
Hydratase)
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Fig 23: Analysis of VDAC1 expression in TF-1 cells depleted of SBDS
compared with scrambled controls.
Upper panel: Cell extracts were fractionated by SDS-PAGE, transferred to
Nitrocellulose and were immunoblotted with antibodies raised to VDAC1, SBDS,
and β-actin. Lower panel: Quantification of band intensity from multiple blots
show increase in VDAC1 expression with SBDS knockdown quantified using
ImageJ software available from the NIH. Graph represents the mean with S.D.
used for error bars. (*p<0.05 as determined by an unpaired Student’s t-test)
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Increased ROS production in cells depleted of SBDS
Decreases in mitochondrial function are often associated with an
increased production of reactive oxygen species. To assess ROS production in
our model system we employed 2',7'-dichlorfluorescein-diacetate (DCFH-DA).
This compound is rapidly cleaved by cellular esterases to the non-fluorescent
compound DCFH. DCFH, in turn, is oxidized to the highly fluorescent compound
DCF in the presence of cellular peroxidases and ROS (Lebel and Bondy, 1990;
Oyama et al., 1994; Rosenkranz et al., 1992; Trayner et al., 1995). Figure 24A
shows that cells depleted of SBDS generate ROS at a rate significantly greater
than that of scrambled controls. Furthermore, steady-state measurements
indicated that cells depleted of SBDS had on average approximately double the
amount of ROS compared to controls (Fig. 24B).
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Fig 24: Analysis of ROS levels in TF-1 cells depleted of SBDS
(A) Representative fluorescence emission with time after treatment with 20 µM
DCFH-DA. (B) Data were plotted as relative fluorescence units in either TF-1
cells depleted of SBDS or scrambled controls. Values represent an average of
three independent experiments. Error bars represent S.D. (*p < 0.05
** p< 0.01 *** p< 0.001 ****p< 0.0001, as determined by an unpaired student’s ttest with earliest time point of specified variation labeled)
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Treatment with a reactive oxygen species scavenger in SDS models has
been shown in prior works to reduce the amount of ROS created with SBDS
knockdown samples (Ambekar et al., 2010). To determine if the enhanced ROS
production in cells depleted of SBDS was limiting growth, we asked whether the
anti-oxidant N-acetyl-cysteine, (NAC), is capable of rescuing the growth deficit
associated with loss of SBDS shown in Figure 16. Figure 25 shows that the
addition of NAC had very complex effects in our tissue culture system. First and
foremost, NAC appears to exhibit a dose dependent toxicity to scrambled control
TF-1 cells. As there are no published studies examining the effects of NAC in
TF-1 cells, it is unclear whether this observation is peculiar to our model system
or is a general characteristic of TF-1 cells. In TF-1 cells depleted of SBDS this
toxicity appears somewhat reduced, and at higher concentrations of NAC growth
appears to be rescued (Fig. 25).
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Fig. 25: Complex effects of NAC on growth and viability of TF-1 cell
cultures.
TF-1 cells transduced with shRNA targeting SBDS or a scrambled control
sequence were treated with the concentrations of NAC shown on the x- axis.
After 24 hours the samples were counted using trypan blue exclusion for cell
viability. Values on the y-axis present the percentage of cell growth during the 24
hour immediately after treatment. Percentages were calculated by the count of
viable cells after treatment divided by the pre-treatment number of cells multiplied
by 100. The numbers shown are the average of three independent experiments
with error bars representing the standard deviation. The red line represents the
x-axis at 0, which represents an equal amount of cell growth and cell death in
the 24 hour time frame.
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Discussion
We have developed a model of SDS that allows us to study aspects of
disease pathophysiology in a human cell line of myeloid lineage. TF-1
erythroleukemic cells transduced with lentiviral vectors targeting SBDS gene
expression were used in these experiments. These cell lines showed less than
30% of scrambled control levels of SBDS mRNA levels and nearly undetectable
protein levels (Fig. 14). The low levels of SBDS observed in our system are a
reasonable approximation to the situation in SDS patients where trace levels of
SBDS are expressed from hypomorphic alleles in this autosomal recessive
disorder (Boocock et al., 2003).
Our models system exhibited many of the hallmarks associated with
reduced SBDS expression in a number of other systems. SBDS is known to
function in ribosome biogenesis. In yeast models of SDS, SBDS is required for
the release of the anti-association factor Tif6, the yeast ortholog of eIF6, from
fully matured 60S subunits in the cytoplasm. The continued presence of Tif6/
eIF6 on 60S subunits in the cytoplasm prevents their association with 40S
subunits in forming 80S initiation complexes and so reduces the translational
capacity of cells. The lack of recycling of Tif6/eIF6 back to the nucleus also
eventually leads to the nuclear accumulation of pre-60S subunits as Tif6/eIF6 is
also required for late steps in the maturation of 60S subunits in the nucleus
(Menne et al., 2007; Moore et al., 2010). In our system the most apparent effect
of the depletion of SBDS on the translational machinery is a reduction in
polysomes consistent with a decrease in the number of functional ribosomes.
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Further we found that this decrease in translational capacity correlated with an
increased presence of eIF6 in the 60S subunit fraction.
Neutropenia is the most common blood lineage dysfunction seen in SDS
with disease severity often relapsing and remitting over time and can often
include other BM lineages (Burroughs et al., 2009). SDS predominantly affects
cells of myleloid lineages which is why we turned to TF-1 cells in creating our
cell-based model. TF-1 cells are able to undergo partial myeloid or erythroid
differentiation when grown in either GM-CSF or EPO, respectively (Miyake et al.,
2005). Our experiments demonstrated that depletion of SBDS reduced
differentiation along both myeloid and erythroid lineages (Fig. 19). Other cell
models have shown that SBDS is an important regulator of differentiation and
proliferation of hematopoietic cells of both erythroid and granulocytic lineages,
which is congruent with our findings and marrow phenotypes observed in SDS
patients (Sen et al., 2011). In addition to the failure to differentiate along
erythroid and granulocytes lineages, the TF-1 cell model reported here also
shows a delay in cell cycle progression associated with decreased SBDS
expression.
A major focus of our efforts with the TF-1 cell model of SDS was to
determine if decreased expression of SBDS would interfere with mitochondrial
function. These experiments were based, in part, on the observation that yeast
cells depleted of Sdo1 were unable to grow on non-fermentable carbon sources.
Another observation that directed us towards an assessment of mitochondrial
function was a recent report indicating that mammalian cells depleted of SBDS
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showed an increase in ROS production. As mitochondria are a major source of
ROS in many cells types and increases in ROS production is sensitive to mild
uncoupling of the mitochondrial membrane potential it seemed reasonable to
hypothesize that cells depleted of SBDS could have compromised mitochondrial
function.
We employed two independent approaches to assess mitochondrial
function in human TF-1 cells depleted of SBDS. The first was to measure
oxygen consumption while the second was to evaluate mitochondrial membrane
potential. The rates of basal and maximal oxygen consumption in SBDS
knockdown cells were reduced relative to scrambled controls (Fig 20). The
effect on basal oxygen consumption appeared greater when comparing the
slopes of oxygen consumption curves before and after CCCP addition. The ratio
in SBDS depleted samples was increased approximately 18% relative to
scrambled controls suggesting there were affects on both mitochondrial mass
and function. The finding that mitochondrial membrane potential also appeared
lower in cells depleted of SBDS is consistent with an effect on mitochondrial
function.
The work outlined here is the first to describe mitochondrial dysfunction in
cells depleted of SBDS. Intriguingly however, these are not the first studies to
link mitochondrial dysfunction to a bone marrow failure syndrome. Pearson’s
syndrome, which is caused by mutations in mitochondrial DNA, is characterized
by anemia/pancytopenia and defective exocrine pancreas failure, reminiscent of
the cardinal pathologies seen in SDS (Lee et al., 2007; Shimamura and Alter,
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2010; Topaloglu et al., 2008; Williams et al., 2012). Whether these two
syndromes will converge to a common underlying pathological mechanism based
on mitochondrial dysfunction remains to be seen.
We have examined the steady-state levels of a number of mitochondrial
proteins to obtain a better perspective on changes brought about on
mitochondrial function in cells depleted of SBDS. We have seen no consistent
pattern of changes in expression of mitochondrial proteins involved in the
organelle import machinery or in antioxidant defense enzymes in response to
SBDS depletion. Two proteins in each of these classes were examined with one
increasing expression and the other decreasing expression in both cases. One
feature of this analysis which may be of note is the finding that proteins directly
involved in energy metabolism, PDH, IDH3α, and cytochrome c are all decreased
in cells depleted of SBDS. A decrease in the activity of the TCA cycle, linked to
reduced IDH3α activity, or reduced acetyl-CoA as a result of decreased activity of
PDH, could have an impact on mitochondrial membrane potential as could lower
amounts of cytochrome c.
Compromised function of the electron transport chain could in principle
lead to an increase in ROS generation such as that observed now in two different
models of SDS and in multiple models of altered cellular metabolism in
carcinogenesis (Ahn et al., 2008; Bell et al., 2011; Bell and Guarente, 2011;
Choudhary et al., 2009; Finley et al., 2011; Haigis et al., 2012; Hanahan and
Weinberg, 2011; Huang et al., 2010; Kim et al., 2010; Schumacker, 2006). While
at present this relationship is simply a correlation, it does represent a fruitful area
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of investigation. The finding that the antioxidant NAC rescues some of the
growth characteristics of cells depleted of SBDS suggests that the increase in
ROS production may be a contributing factors to SDS pathophysiology.
Finally, similar to what was observed in yeast we see an increase in the
amount of VDAC1 in cells depleted of SBDS. Both increased and decreased
expression of VDAC1 has been linked to apoptosis and so it is possible that
changes in VDAC levels could potentially contribute to enhanced cell death in
cellular models of SDS.
Changes in particular mitochondrial proteins, in addition to VDAC1, are
reminiscent of other experiments performed in our lab and the works of others.
Joseph Moore IV, formerly of the Ellis lab and in collaboration with researchers at
Texas A & M, performed a drug screen for rescue of the growth deficit of SDO1
yeast strains. They discovered that the HDAC inhibitor TSA could lead to global
changes in protein expression and acetylation that mimicked the wild-type
samples as well as rescuing the growth deficit. In other settings where global
protein acetylation is affected by loss of a protein responsible for deacetylation,
loss of SIRT3, a member of another HDAC family, in both mouse models and
yeast strains, leads to changes in global protein acetylation (Ahn et al., 2008;
Choudhary et al., 2009; Kim et al., 2010; Tao et al., 2010). It is one of a class of
acetylation regulating enzymes called sirtuins, and this particular one is the major
mitochondrial form that functions as an NAD-dependent de-acetylase. For
example, the mitochondrial reactive oxygen species scavenger SOD2 is
hyperacetylated and cannot perform its normal functions efficiently (Tao et al.,
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2010). This prevents the mitochondria from dealing with normal concentrations
of superoxide radicals while simultaneously in this system Hif1α, a hypoxia
induced transcription factor, increases the expression of gene targets responsible
for the so-called Warburg effect(Bell et al., 2011; Bell and Guarente, 2011; Finley
et al., 2011). The Warburg effect is the mechanism by which cancerous cells
preferentially metabolize glucose, even at the expense of generating large
concentrations of reactive oxygen intermediates through inefficient oxidative
respiration (Schumacker, 2006; Warburg, 1956). The acetylation status of
multiple proteins, in addition to the changes in protein expression mediated by
Hif1α, promote the reprogramming of cellular metabolism and the drive toward
glycolysis as the sole energy producing pathway (Ahn et al., 2008; Choudhary et
al., 2009; Finley et al., 2011; Haigis et al., 2012; Hanahan and Weinberg, 2011;
Huang et al., 2010; Kim et al., 2010; Tao et al., 2010). One downstream
modification is to decrease expression of SOD2. Thus, overall ROS levels are
increased by two mechanisms, both an increase in the production of ROS from
the increased activity of the electron transport chain given the cell’s preference
for metabolism of glucose, and a decrease in protein levels of SOD2 and the
efficiency of super oxide radical scavenging of the individual SOD2 proteins due
to hyper-acetylation (Ahn et al., 2008; Bell et al., 2011; Bell and Guarente, 2011;
Finley et al., 2011; Haigis et al., 2012; Kim et al., 2010; Tao et al., 2010). There
are questions left to answer in the complex interplay between SBDS, ROS, and
the function of the mitochondria in SDS pathophysiology.
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Together, our findings point to mitochondria as a source of new
physiologic functions for SBDS, which adds to its reported roles in ribosome
synthesis, chemotaxis, and mitotic spindle assembly (Ambekar et al., 2010;
Austin et al., 2008; Ball et al., 2009; Brina et al., 2011; Finch et al., 2011;
Ganapathi et al., 2007; Leung et al., 2011; Nihrane et al., 2009; Orelio et al.,
2011; Orelio et al., 2009; Rawls et al., 2007; Sen et al., 2011; Smith et al., 1996;
Watanabe et al., 2009; Wong et al., 2011; Yamaguchi et al., 2011; Yamaguchi et
al., 2007).
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Conclusions and Future Directions
The complex role of SBDS in cellular metabolism and respiration is
inevitably far more intricate than the scope of this dissertation work. These
studies were initiated to follow up on the observation that yeast lacking Sdo1, the
Sbds ortholog, were unable to grow on non-fermentable carbon sources
indicating a defect in mitochondrial function. We used multiple approaches to
study mitochondrial function in human cells depleted of SBDS, each of which
were consistent with a role for SBDS in maintaining mitochondrial function.
These studies present a new avenue of investigation into the pathophysiology of
Shwachman Diamond syndrome. Moreover, they also present new opportunities
for therapeutic intervention.
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APPENDIX I

Initial Remarks
Research studies that did not easily fall under the same umbrella as the
major works of my dissertation are found in the following sections. These topics
include verification of ribosome defects in an inducible mouse model of Rps19
shRNA and mouse embryonic stem cell (mES) models, all relating to Diamond
Blackfan anemia (DBA). The mES models mimic haploinsufficiency for both
Rps19 and Rpl5 in different cell lines, providing a tool for comparison of different
DBA genes.
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Supplemental Section 1: Mouse Embryonic Stem Cell Model

Introduction
Macrocytic anemia of variable severity is the unifying feature of DBA
diagnosis (Lipton et al., 1986). Bone marrow biopsy is central in classifying this
inherited bone marrow failure syndrome. Classical DBA shows a red cell specific
propensity for apoptosis in erythroid progenitors with an otherwise normocellular
bone marrow (Miyake et al., 2008; Ohene-Abuakwa et al., 2005; Perdahl et al.,
1994; Tsai et al., 1989). Having a valid animal model to gain understanding of the
molecular mechanisms that result in the vast array of features associated with a
mutlifactoral disease such as DBA is of paramount importance. In addition to
potential advances in whole animal models, recapitulating central events in
hematopoiesis in a tissue culture system could provide an alternative
methodology to study DBA pathophysiology in the absence of a suitable animal
model. Stem cell cultures have been used to mimic differentiation of progenitors
and study erythropoiesis defects in other contexts, but not in DBA (Choi, 1998;
Keller, 2005) To this end, mouse embryonic stem cells were used to mimic
haploinsufficiency for known DBA genes. These gene trap constructs were
created by retroviral insertion within the genes for Rps19 or Rpl5 that causes a
premature termination of the gene transcript in only one copy of the gene (Keller,
2005) . With appropriate culture conditions and appropriate cytokine stimulation
they can be induced to differentiation into blood lineage specific colonies in the
manner shown in Fig. S1.
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Fig S1: Embryonic stem cell culture recapitulates hematopoiesis in mouse
models.
Differentiation of mES models can be used to mimic the in vivo erythrocyte
development with representative images of ES cell and embryoid bodies (EBs)
shown in the inset pictures. Adapted from previous works (Keller, 2005).
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Stem cells in this system can be grown in an undifferentiated state to
represent the HSC multipotent progenitor or undergo primary differentiation in
methylcellulose media to form embryoid bodies. The viscous nature of
methylcellulose is necessary for the sensitive stem cell progenitors to receive
appropriate structural interactions with the surrounding environment to
differentiate. On specific days of differentiation, as outlined in the in vitro time
line of Fig. S1, the EBs can be harvested and induced to form primitive or
definitive erythroid colonies. Primitive erythroid colonies express variants of
hemoglobin specific to fetal development, such as Hbb-bh1. This can be thought
of as analogous to the fetal hemoglobin chains produced during human
embryogenesis (Hb-F = Hemoglobin Fetal). Definitive erythropoiesis is
responsible for the production of red cells in adult animals and can be modeled
by harvesting EBs later in their development before inducing differentiation with
SCF (Stem cell factor), IL-3, IL-6, and epo to form burst forming units of the
erythroid lineage (BFU-Es). In mice adult hemoglobin is Hbb-b1.
The mES models represented here were described earlier in the materials
and methods section, but will be briefly reviewed here. Two different cell lines
heterozygous for Rps19 were used in an attempt to recapitulate the pathology of
haploinsufficiency for Rps19. The S17-10H1 line was created by genetrap
insertion between exon 2 and 3 in the Rps19 gene of the Ak7 mouse parental
line. A “rescue” of this cell line was generated by electroporation of a plasmid
expressing Rps19 from a cDNA insert and termed “ORF-S17.” Because the
electroporation necessitated antibiotic selection, an empty vector plasmid was
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also electroportated into the S17 cell line and called “EMT-S17.” Both lines were
screened for uptake of the plasmid using puromycin selection. Effectively the
EMT-S17 should model the original gene trap line, with one copy of Rps19
inactivated, and the ORF-S17 should serve as a control line. The second Rps19
model of haploinsufficiency has a gene trap insertion between exons three and
four of the E14 parental cell line to generate the YHC074 gene trap line. The
Rpl5 model was created by gene trap insertion between exon three and four of
the Rpl5 gene in the parental TBV cell line to generate the D050 mutant line (Fig
3 and 4 of Chapter 3).
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Results
In order to establish the gene trap cell lines as useful models of DBA,
reduced expression of the gene products that have been targeted must be
established. All three cell lines were found to contain the reporter gene mRNA by
qRT-PCR as well as knockdown of the mRNA transcript for Rps19 or Rpl5 where
appropriate (personal communication via Dr. Tracie Goldberg and Dr. Sharon
Singh of the Feinstein Institute for Medical Research, data not shown). The
Rps19 mES cells provided the most consistent and reproducible protein
knockdown (Fig. S2). Our collaborators at the Feinstein Institute were able to
show an initial protein knockdown in the Rpl5 samples (Fig. S3).
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Fig S2: Protein knockdown of Rps19 in mES cells evidenced by
immunoblotting.
Whole cell lysates were used for immunoblotting using antibodies raised against
Rps19 and β-Actin. (A) YHC (Rps19 gene trap) and corresponding E14 parental
control blotted for Rps19 and β-Actin. Band density was quantified by ImageJ
software and showed an ~80% knockdown of Rps19 protein expression relative
to the β-Actin loading control. (B) ORF-S17 and EMT-S17 mES gene trap
samples grown with or without antibiotic selection to maintain the gene trap
construct.

The ORF-S17 is a corrected clone of the gene trap and therefore

used as a control, while the EMT-S17 only has one functional copy of Rps19.
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The blot was quantified using ImageJ and was determined to have approximately
30% knockdown of Rps19 protein expression relative to β-Actin loading control.
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Fig S3: Protein knockdown of Rpl5 in mES gene trap samples.
D050 Rpl5 mutants and their corresponding YHC parental control mES whole
cell lysates were Western blotted for Rpl5 and β-Actin expression by Dr. Tracie
Goldberg.
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In addition mRNA and protein knockdown, characteristic processing
defects in the maturation of rRNA as outlined in Chapter three should also be
present. Total RNA was isolated from mES cells and used for Northern blotting
as previously outlined (Flygare et al., 2007). In both DBA patients and cell
culture models with haploinsufficiency for Rps19, there is a delay in the
processing of 18S rRNA that can be identified at the cleavage step of 21S prerRNA into the more mature 18SE pre-rRNA when total RNA is Northern blotted
using a probe called “18SE.” This probe is complementary to the 3’ end of the
18S rRNA and the 5’ end of ITS1. This processing defect is evident as an
increase in the ratio of the 21S precursor relative to 18SE. Figure S4 shows a
representative Northern blot of the YHC Rps19 mutant cell line and its parental
control, E14. The average ratio of 21S to 18SE in four separate experiments in
represented in the bar graph next to the blot. This increase in the 21S:18SE ratio
represents an average 1.55 fold change when the mutant is normalized to the
parental sample, which is on par with the inducible mouse model presented in
supplemental section 2.
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Fig S4: Mouse embryonic stem cells (mES) heterozygous for Rps19
display processing defects in pre-rRNA expected for Rps19
haploinsufficiency.
Representative Northern blot (left) and quantification of replicate data of total
RNA harvested from mES cells with gene trap for Rps19 and parental controls.
An increased ratio of 21S to 18SE pre-rRNA is evident. This delay in the prerRNA processing was reproducible and statistically significant. (Bar graph
represents the mean, with S.D. used for error bars, n=4, *p<0.05. As determined
by an unpaired Student’s t-test)
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To determine if the gene trap cell lines affected the production of ribosomal
subunits we also analzyed polysome profiles from these cell lines. Figures S5
and S6 show representative polysome profiles from mES samples.
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Fig. S5: mES samples with haploinsufficiency for Rpl5 show a decrease in
polysome size.
(A) A schematic representing changes in polysome profiles depending on which
ribosomal subunit is affected. Polysome profiling gives a general overview of the
translational machinery in cells. The number of ribosomes translating a given
mRNA at any time is dependent on the rates of initiation, elongation, and
termination as shown in the top example in portion (A). Changes in levels of the
40S and 60S subunits typically affect initiation giving smaller polysomes. The
larger the number of ribosomes on a message the higher the initiation rate.
When the 40S subunit becomes limiting, such as in models of Rps19
haploinsufficiecy represented in the middle schematic, there are fewer ribosomes
attached to a given mRNA, causing a left shift in polysomes and a relative
excess of free 60S subunits. This occurs because the 40S subunit must bind to
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the mRNA first before a pre-initiation complex can prepared for subsequent 60S
subunit binding. The bottom example, in which 60S subunits are limiting, as in
Rpl5 haploinsufficiency, a 40S subunit may be attached to the mRNA, but has
difficulty locating a 60S subunit capable of binding to it which leads to fewer 80S
initiation complexes formed and reduced initiation rates.
(B) This shows a representative polysome profile from mES samples with a gene
trap targeting Rpl5. The parental cell line absorbance tracing (YHC) is shown in
black with the mutant (D050) absorbance tracing shown in red. Though the 60S
subunit peak does not seem to be as severely affected as in the Rps19 models
to follow, a modest defect appears in the polysome region and a slight leftward
shift in polysomes indicating initiation rates may be affected.
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Fig. S6: mES polysome profiles in Rps19 genetrap.
Two mES cell lines with gene traps targeting Rps19 were treated with
cyclohexamide and harvested for polysome profiling. (A) The parental E14 mES
line generated the absorbance tracing shown in black and the mutant YHC
absorbance tracing was overlaid in red. When normalized to the 40S subunit,
there is an appreciable relative decrease in the 80S subunit. The 60S subunit
appears to be proportionally increased, but this is to be expected in the setting of
abortive ribosomal assembly of 40S subunits when Rps19 is in limiting quantities.
(B) A representative absorbance tracing of the ORF-S17 mES gene trap with
corrected Rps19 protein expression is shown in black and the EMT-S17, mutant
mES cell line is overlaid in red. The most appreciable defects in this system are
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found in both the 80S subunit formation decrease and also as a trend toward
smaller polysomes in the polysome region of the profile.
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Discussion
The protein knockdown of the ribosomal proteins targeted by the gene
trap cell lines in addition to the ribosomal defects shown in polysome profiles, are
suggestive of a specific subunit defect. At best, these data are far from concrete,
but demonstration of ribosome synthesis deficiencies have never been as robust
as those in human model systems. In addition to the ribosomal biology findings
presented in the results section, collaborators at the Feinstein Institute made
several important findings not presented as data in this dissertation.
They have been able to demonstrate defects in embryoid body formation
as well as the ability to generate hematopoietic type colonies in all three cell
lines, but the Rpl5 line uniquely generated smaller individual embryoid bodies.
Preliminary data has shown a decreased ability for definitive erythropoiesis in all
three cell lines, but the YHC cell line was able to maintain the efficiency of
primitive erythropoiesis. There was also an increase in the p53 expression
based on flow cytometry, but the initial experiments are not yet replicated. All
defects tested were rescued by either p53 inactivation or cDNA re-expression of
the gene targeted in the gene trap.

Additionally, knockdown of Rpl11

expression in addition to the original genetrap defects increased all measureable
defects. We hypothesize this is due to the role of Rpl11 in the MDM2-p53
pathway in cooperation with 5S rRNA and Rpl5.
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Conclusions and Future Directions
The mES model represented here is taking shape as a method to
recapitulate and further investigate the molecular mechanisms leading to the
block in maturation of erythroid precursors in DBA. There are several studies
represented here and in the works of our collaborators that need to be replicated
and statistically analyzed. Once these findings are determined to be reproducible
they can be used to test potential therapies. It represents a model of
haploinsufficiency that has been difficult to produce in whole animal models. As
a tissue culture method, it offers a high throughput method to screen multiple
drugs, or other therapies, and generate a specific dose response to a positively
screened compound. Also, it has the specific advantage of analysis at the
specific phases of hematopoietic differentiation of HSC that is the unifying feature
of the constellation of features that make DBA a diagnostic and therapeutic
challenge. If the defect in maturation of pre-erythroid cells can be reversed in
this model, the potential validity is greatly increased. It certainly lends itself well
to a pre-screening of potential therapies before the needless sacrifice of animals
to potentially hazardous treatments.
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Section 2: Inducible Rps19 Depletion Mouse Model

Introduction
This section represents some data used in the manuscript, Jaako et al in
Blood 2011 (Jaako et al., 2011), though all figures used were newly adapted for
this dissertation. This section outlines the validation of a potential mouse model
for DBA. An inducible knockdown of the most common DBA gene, Rps19, was
developed to circumvent several pitfalls of previous animal models. By allowing
for normal expression of ribosomal protein genes during fetal development, the
embryonic lethality shown with the homozygous deletion of Rps19 (Matsson et
al., 2004) was avoided, and by adding one or two copies of an inducible shRNA
to the genome of the animal theoretically creates an ability to express a broad
range of Rps19 knockdown levels. Thus, this animal model is uniquely poised to
display phenotypic manifestations of Rps19 knockdown in contrast to the
heterozygous knockout mouse that showed very few changes in any of the
originally measured parameters (Matsson et al., 2004).
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Results
Embryonic fibroblasts (MEF) cells were harvested for growth in tissue
culture as previously described (Jaako et al., 2011). As outlined in the methods
section, the samples contained one (genotypes B/+ and D/+) or two (genotype B/
B) copies of an inducible shRNA sequence targeting Rps19 mRNA labeled “B” or
“D,” under control of a tet-on promoter located in the collagen A1 locus.
MEF samples grown in culture in the presence of doxycycline were
compared to untreated control cultures of the same genotype (labeled +/+). Total
RNA was harvested from these cultures and used for Northern blot analysis to
detect processing defects in the production of pre rRNA. Figure S7A details the
portion of the pre-rRNA processing pathway examined using the “18SE” probe
next to a representative Northern blot image. Both shRNA sequences increased
the ratio of the immature 21S precursor pre rRNA relative to the downstream
cleavage product 18SE pre-rRNA to a statistically significant level (Fig S7C).
Mice given doxycycline in their drinking water for two weeks were sacrificed and
their livers used for the same Northern blot analysis produced similar delays in
the processing of pre-rRNA (Fig S7B).
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Fig S7: Pre-rRNA processing defects associate with inducible Rps19
shRNA expressing mouse model.
(A) Representative Northern blot of control (+/+) or single copy B shRNA
targeting Rps19 (B/+) MEF total RNA labeled with 18SE oligo on the left and the
corresponding pre-rRNA species on the right. (B) Fold change in the ratio of
21S:18SE pre-rRNA species normalized to the ratio in the control MEF harvested
after seven days of treatment with doxycycline (n=4, * p<0.05).
(C) Fold changes in the ratio of 21S:18SE pre-rRNA species normalized to the
ratio in the control. Total RNA from animals given doxycycline in their drinking
water for fourteen days expressing B (B/+) or D (D/+) sequence shRNA to target
Rps19 gene expression.
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MEF samples grown in culture, as well as liver and bone marrow samples
harvested from animals treated with doxycycline for two weeks were used for
polysome profiling. Figure S8 shows representative absorbance tracings from
MEF, liver, and bone marrow samples. Peak intensity corresponds to the relative
amount of polysomes in each peak.
MEF samples (Fig S8A) show a decrease in 40S and 80S subunits similar
to profiles in bone marrow samples (Fig. S8C). Liver samples of the B/+
genotype show a relative increase in the free 60S pool as well as defects in 80S
formation (Fig S8B). Liver samples of the D/+ genotype show a more
pronounced 40S subunit defect as well as an 80S biogenesis decrease and a
slight decrease in the absorbance of the polysome region (Fig S8D).
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Fig S8: Polysome profiles of different cells and tissues from an inducible
Rps19 shRNA mouse model.
(A) MEF control and (B/+) (B) Liver control and (B/+) (C) Bone marrow control
and (B/+) and (D) Liver control and (D/+) representative absorbance tracings of
cells harvested in cycloheximide and separated by size by ultracentrifugation on
sucrose gradients.
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Printed absorbance tracings were trimmed at the baseline of each peak
and the weight of the different peaks measured. The absorbance peak can be
thought of as an integral such that the area under the curve (weight) is
proportional to the number of polysomes in that peak. Liver polysome profile
samples provided the most robust examples of small subunit deficiency in
comparison to other tissue types sampled in these experiments, and peaks were
weighed using this method. Peak weight is shown as a percentage of the 40S
subunit weight normalized to the 40S subunit in Fig S9.
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Fig S9: Peak weights of liver rRNA species separated on sucrose gradients
and identified by polysome profiling.
Ribosomal RNA species were identified in absorbance tracings, and peaks cut
out individually from the tracing and weighed. The bar graph represents each
peak as a percentage of total profile weight normalized to the 40S subunit (n=6,
*p<0.05 as determined by an unpaired Student’s t-test)
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Discussion
Multiple publications have shown a delay in the processing of pre-rRNA
from the polycistronic 45S precursor that generates the mature 18S, 5.8S, and
28S rRNA species in both patient samples and animal models (Flygare et al.,
2007; Jaako et al., 2011; Robledo et al., 2008). This model showed similar
increases in the ratio of 21S: 18SE pre-rRNA in both MEF (Fig. S7A and S7B)
and liver (Fig. S7C) samples further validating this ratio as a method for
measuring functional consequences of Rps19 deficiency.
Polysome profile analyses were similarly supportive of a specific small
subunit defect (Fig. S7). The top left panel shows a representative diagram of
MEF samples normalized to the 60S subunit absorbance peak to highlight a
corresponding decrease in the absorbance maximum for 40S subunits as well as
80S subunits, which is what would be predicted with a limiting quantity of 40S
subunits. This pattern was recapitulated in the liver samples with one inducible
copy of the D shRNA shown in the bottom right panel. Normalizing the liver
samples with one copy of the B shRNA sequence to the 40S subunit also
highlights a relative increase in the 60S subunit and decrease in the 80S subunit
and polysome region shown in the top right panel. At the time of submission of
this dissertation, I am unaware of any other work that has shown polysome
profiles generated from bone marrow samples. The bottom left panel shows near
absence of the 40S subunit as well as a decrease in the 80S peak absorbance.
This data is less than ideal, but given the bone marrow failure of the animals
depleted of Rps19, the starting material for this experiment was of limiting
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quantities. In liver samples each peak weight as a percentage of the total profile
weight was graphed in Fig S8. The shRNA sequence “D” was shown to have a
greater effect on Rps19 gene expression (data not shown) and a statistically
significant decrease in 40S subunit weight. The 80S subunits of each of the
Rps19 knockdown liver sample genotypes were shown to decrease, further
supporting the functional lack of 40S subunits due to a decrease in Rps19.
Though data was not shown in the manuscript, the mouse model central
to these studies recapitulated many of the hematopoietic defects pathognomonic
of DBA in addition to the ribosomal defects outlined above. These animals
exhibit a macrocytic anemia, with additional defects in other blood lineages,
which is not uncommon in the heterogeneous presentation of DBA (Farrar and
Dahl, 2011). These animals also display symptoms of bone marrow failure over
time based on competitive transplantation assay, which is a hallmark of DBA
pathophysiology. The phenotype could be rescued by ectopic expression of
Rps19 or loss of p53, cementing the specificity of the model (Jaako et al., 2011).

197

Conclusions and Future Directions
The molecular signatures highlighted by this work were previously
published (Jaako et al., 2011). Without careful validation of the molecular
pathophysiology characteristic of DBA, the specificity of an animal model is in
question. The pre-rRNA processing and polysome profile defects link the bone
marrow failure shown in the animal model to specific defects in Rps19. Now that
this model has been validated, it has enormous potential in drug discovery and
design, as well as more detailed inspection of the diverse biological pathways
involved in DBA pathophysiology.
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APPENDIX II

Abbreviations
CGH- comparative genomic hybridization
DBA- Diamond Blackfan Anemia
DC- Dyskeratosis Congenita
DMEM- dublbecco’s modified eagle media
DNA- deoxyribonucleic acid
DTT- dithiothreitol
EB- embryoid body
Ex- exon
FBS – fetal bovine serum
FA- Fanconi Anemia
FFME - formaldehyde, formamide,MOPS, ethidium
FISH – flow in-situ hybridization
GMCSF- granulocyte macrophage colony stimulating factor
HRP- horse radish peroxidase
IBMFS- inherited bone marrow failure syndrome
IMM- inner mitochondrial membrane
IMS- intermembrane space
ITS- internal transcribed sequence
IDH- isocitrate dehydrogenase
LTR- long terminal repeat
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MM- mitochondrial matrix
MEF- mouse embryonic fibroblasts
mES- mouse embryonic stem cells
mLIF- mouse leukemia inhibitory factor
MMRRC- mutant mouse regional resource center
mRNA – messenger RNA
MTG – monotioglycerol
OMM- outer mitochondrial membrane
ORF- open reading frame
P/S- penicillin and streptomycin solution
PDH- pyruvate dehydrogenase
RNA- ribonucleic acid
ROS- reactive oxygen species
RPL- ribosomal protein of the large subunit
RPS- ribosomal protein of the small subunit
rRNA- ribosomal RNA
SA- splice acceptor
SCN- severe congenital neutropenia
SD- splice donor
SDS- Shwachman Diamond Syndrome
SnoRNP- small nucleolar ribonuclear protein
SOD2- super oxide dismutase 2 (mitochondrial)
TOMM- transfer channel of the outer mitochondrial membrane
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tRNA- transfer RNA
TSA- trichostatin A
VDAC- voltage dependent anion channel

Gene Abbreviations
eIF6- eukaryotic initiation factor 6
RPS19 (Rps19)- small ribosomal subunit protein 19
RPL5 (Rpl5)- large ribosomal subunit protein 5
RPL11 (Rpl11)- large ribosomal subunit protein 11
SBDS – shwachman bodian diamond syndrome protein
SIRT3- NAD(+) dependent deacetylase sirtuin 3, mitochondrial
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